Kraig Biocraft Laboratories (KBLB) S-1/A 25 Aug 21 IPO registration (amended) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2021
Cover [Abstract]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	PRE-EFFECTIVE AMENDMENT NO. 5
Entity Registrant Name	KRAIG BIOCRAFT LABORATORIES, INC.
Entity Central Index Key	0001413119
Entity Tax Identification Number	83-0459707
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	2723 South State St. Suite 150
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48104
City Area Code	(734)
Local Phone Number	619-8066
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash	$ 3,667,540	$ 816,907	$ 125,024
Prepaid expenses	1,698	2,588	31,745
Total Current Assets	3,669,238	819,495	156,769
Property and Equipment, net	80,921	89,247	117,321
Operating lease right-of-use asset, net	332,214	365,025	473,242
Security deposit	3,518	3,518	3,518
Total Assets	4,085,891	1,277,285	750,850
Current Liabilities
Accounts payable and accrued expenses	691,164	600,003	560,948
Note payable - related party	1,657,000	1,657,000	642,000
Royalty agreement payable - related party	65,292	65,292	65,292
Accounts payable and accrued expenses - related party	5,027,638	4,802,985	4,145,465
Operating lease liability, current	115,995	124,909	110,678
Loan payable	60,000	60,000	60,000
Convertible note payable	1,134,973	50,505
SBA Paycheck Protection Loan		90,100
Total Current Liabilities	8,752,062	7,450,794	5,584,383
Long Term Liabilities
Loan payable, net of current	120,244	145,244	185,244
Operating lease liability, net of current	228,690	254,811	369,281
Total Liabilities	9,100,996	7,850,849	6,138,908
Commitments and Contingencies
Stockholders’ Deficit
Preferred stock, value
Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively	22,000	22,000	22,000
Additional paid-in capital	9,572,046	5,833,583	2,412,969
Deferred Compensation
Accumulated Deficit	(38,463,620)	(34,769,183)	(29,797,906)
Total Stockholders’ Deficit	(5,015,105)	(6,573,564)	(5,388,058)
Total Liabilities and Stockholders’ Deficit	4,085,891	1,277,285	750,850
Series A Preferred Stock [Member]
Stockholders’ Deficit
Preferred stock, value	5,217,800	5,217,800	5,217,800
Common Class A [Member]
Stockholders’ Deficit
Common stock, value	18,636,669	17,122,236	16,757,079
Common Class B [Member]
Stockholders’ Deficit
Common stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Convertible note payable, net of debt discount	$ 2,865,027	$ 949,495	$ 0
Preferred stock, no par value	$ 0	$ 0	$ 0
Preferred stock, shares authorized	Unlimited	Unlimited	Unlimited
Preferred stock, shares outstanding	0	0	0
Preferred stock, shares issued		0	0
Common stock issuable	1,122,311	1,122,311	1,122,311
Convertible note payable, net of debt discount		$ 949,495
Series A Preferred Stock [Member]
Preferred stock, no par value	$ 0	$ 0	$ 0
Preferred stock, shares outstanding	2	2	2
Preferred stock, shares issued	2	2	2
Common Class A [Member]
Common stock, no par value	$ 0	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited	Unlimited
Common stock, shares issued	868,038,875	854,410,001	844,468,378
Common stock, shares outstanding	868,038,875	854,410,001	844,468,378
Common Class B [Member]
Common stock, no par value	$ 0	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited	Unlimited
Common stock, shares issued	0	0	0
Common stock, shares outstanding	0	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating Expenses
General and Administrative	369,312	348,278	675,899	3,141,059	3,518,527	1,413,982
Professional Fees	119,038	31,100	226,523	50,474	397,727	342,845
Officer’s Salary	171,694	54,853	331,592	199,415	516,332	627,197
Rent - Related Party	410	3,128	3,683	6,263	13,092	14,793
Research and Development	44,726	32,970	132,494	37,782	88,470	223,050
Total Operating Expenses	705,180	470,329	1,370,191	3,434,993	4,534,148	2,621,867
Loss from Operations	(705,180)	(470,329)	(1,370,191)	(3,434,993)	(4,534,148)	(2,621,867)
Other Income/(Expenses)
Gain on debt extinguishment (PPP)			90,100
Interest expense	(199,619)	(98,468)	(329,878)	(185,143)	(386,624)	(294,352)
Amortization of original issue discount	(1,848,976)		(2,084,468)		(50,505)
Interest income						6,369
Total Other Income/(Expenses)	(2,048,595)	(98,468)	(2,324,246)	(185,143)	(437,129)	(287,983)
Net (Loss) before Provision for Income Taxes	(2,753,775)	(568,797)	(3,694,437)	(3,620,136)	(4,971,277)	(2,909,850)
Provision for Income Taxes
Net (Loss)	$ (2,753,775)	$ (568,797)	$ (3,694,437)	$ (3,620,136)	$ (4,971,277)	$ (2,909,850)
Net Income (Loss) Per Share - Basic and Diluted	$ 0	$ 0	$ 0	$ 0	$ (0.01)	$ 0
Weighted average number of shares outstanding during the period - Basic and Diluted	859,825,411	844,468,378	858,563,969	844,468,378	848,651,465	835,587,422

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders Deficit (Unaudited) - USD ($)	Series A Preferred Stocks [Member]	Common Class A Stock [Member]	Common Class B Stock [Member]	Common Stock Class A Shares to be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning Balance at Dec. 31, 2018	$ 5,217,800	$ 15,145,798		$ 22,000	$ 2,043,235	$ (26,888,056)	$ (4,459,223)
Beginning balance, shares at Dec. 31, 2018	2	816,883,910		1,122,311
Units issued for cash		$ 1,000,000					1,000,000
Units issued for cash, shares		14,797,278
Shares issued in exchange for accounts payable		$ 281,659					281,659
Shares issued in exchange for accounts payable, shares		4,052,652
Cancellation of warrants issued for services					(19,915)		(19,915)
Warrants issued for services - related parties					669,248		669,248
Warrants issued for services					27,686		27,686
Exercise of warrants in exchange for stock		$ 329,622			(329,622)
Exercise of warrants in exchange for stock, shares		8,734,538
Imputed interest - related party					22,337		22,337
Net loss						(2,909,850)	(2,909,850)
Ending Balance at Dec. 31, 2019	$ 5,217,800	$ 16,757,079		$ 22,000	2,412,969	(29,797,906)	(5,388,058)
Ending balance, shares at Dec. 31, 2019	2	844,468,378		1,122,311
Warrants issued for services - related parties					2,612,411		2,612,411
Warrants issued for services					42,713		42,713
Contributed capital - related party					17,495		17,495
Imputed interest - related party					21,972		21,972
Net loss						(3,620,136)	(3,620,136)
Ending Balance at Jun. 30, 2020	$ 5,217,800	$ 16,757,079		$ 22,000	5,107,560	(33,418,042)	(6,313,603)
Ending balance, shares at Jun. 30, 2020	2	844,468,378		1,122,311
Beginning Balance at Dec. 31, 2019	$ 5,217,800	$ 16,757,079		$ 22,000	2,412,969	(29,797,906)	(5,388,058)
Beginning balance, shares at Dec. 31, 2019	2	844,468,378		1,122,311
Warrants issued for services - related parties					2,794,696		2,794,696
Warrants issued for services					50,763		50,763
Exercise of warrants in exchange for stock		$ 365,157			(365,157)
Exercise of warrants in exchange for stock, shares		9,941,623
Contributed capital - related party					17,495		17,495
Imputed interest - related party					58,817		58,817
Beneficial conversion feature					864,000		864,000
Net loss						(4,971,277)	(4,971,277)
Ending Balance at Dec. 31, 2020	$ 5,217,800	$ 17,122,236		$ 22,000	5,833,583	(34,769,183)	(6,573,564)
Ending balance, shares at Dec. 31, 2020	2	854,410,001		1,122,311
Beginning Balance at Mar. 31, 2020	$ 5,217,800	$ 16,757,079		$ 22,000	4,966,968	(32,849,245)	(5,885,398)
Beginning balance, shares at Mar. 31, 2020	2	844,468,378		1,122,311
Warrants issued for services - related parties					110,909		110,909
Contributed capital - related party					17,495		17,495
Imputed interest - related party					12,188		12,188
Net loss						(568,797)	(568,797)
Ending Balance at Jun. 30, 2020	$ 5,217,800	$ 16,757,079		$ 22,000	5,107,560	(33,418,042)	(6,313,603)
Ending balance, shares at Jun. 30, 2020	2	844,468,378		1,122,311
Beginning Balance at Dec. 31, 2020	$ 5,217,800	$ 17,122,236		$ 22,000	5,833,583	(34,769,183)	(6,573,564)
Beginning balance, shares at Dec. 31, 2020	2	854,410,001		1,122,311
Warrants issued for services - related parties					338,831		338,831
Warrants issued for services					23,787		23,787
Exercise of warrants in exchange for stock		$ 470,091			(292,533)		177,558
Exercise of warrants in exchange for stock, shares		3,816,522
Cancellations of warrants					(42,707)		(42,707)
Convertible debt conversion into common stock ($0.0868-$0.1232/Sh)		$ 1,044,342					1,044,342
Convertible debt conversion into common stock ($0.0868-$0.1232/Sh)		9,812,352
Imputed interest - related party					41,085		41,085
Beneficial conversion feature					3,670,000		3,670,000
Net loss						(3,694,437)	(3,694,437)
Ending Balance at Jun. 30, 2021	$ 5,217,800	$ 18,636,669		$ 22,000	9,572,046	(38,463,620)	(5,015,105)
Ending balance, shares at Jun. 30, 2021	2	868,038,875		1,122,311
Beginning Balance at Mar. 31, 2021	$ 5,217,800	$ 17,503,553		$ 22,000	6,089,725	(35,709,845)	(6,876,767)
Beginning balance, shares at Mar. 31, 2021	2	856,746,795		1,122,311
Warrants issued for services - related parties					233,736		233,736
Warrants issued for services					7,929		7,929
Exercise of warrants in exchange for stock		$ 88,774					88,774
Exercise of warrants in exchange for stock, shares		1,479,728
Convertible debt conversion into common stock ($0.0868-$0.1232/Sh)		$ 1,044,342					1,044,342
Convertible debt conversion into common stock ($0.0868-$0.1232/Sh)		9,812,352
Imputed interest - related party					20,656		20,656
Beneficial conversion feature					3,220,000		3,220,000
Net loss						(2,753,775)	(2,753,775)
Ending Balance at Jun. 30, 2021	$ 5,217,800	$ 18,636,669		$ 22,000	$ 9,572,046	$ (38,463,620)	$ (5,015,105)
Ending balance, shares at Jun. 30, 2021	2	868,038,875		1,122,311

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Stockholders Deficit (Unaudited) (Parenthetical)	3 Months Ended	6 Months Ended
	Jun. 30, 2021$ / sharesshares	Jun. 30, 2021$ / sharesshares
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Exercise of warrants | shares	1,479,728	3,816,522
Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Conversion price per share	$ 0.1232	$ 0.1232
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Conversion price per share	$ 0.0868	$ 0.0868

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities:
Net Loss	$ (3,694,437)	$ (3,620,136)	$ (4,971,277)	$ (2,909,850)
Adjustments to reconcile net loss to net cash used in operations
Depreciation expense	13,446	13,118	28,074	30,781
Gain on debt extinguishment (PPP)	(90,100)
Amortization of original issue discount	2,084,468		50,505
Imputed interest - related party	41,085	21,972	58,817	22,337
Fair value of options issued for services		2,655,124	2,845,459	696,937
Warrants issued/(cancelled) to consultants	319,911			(19,915)
Changes in operating assets and liabilities:
Decrease (Increase) in prepaid expenses	890	23,273	29,157	(24,887)
Operating lease right-of-use, net	68,254	57,993	108,217	86,326
Increase in accrued expenses and other payables - related party	224,653	277,050	657,520	795,633
(Decrease)Increase in accounts payable	135,503	(72,448)	39,055	314,369
Operating lease liabilities, current	(70,478)	(53,855)	(100,239)	(79,609)
Net Cash Used In Operating Activities	(966,805)	(697,909)	(1,254,712)	(1,087,878)
Cash Flows From Investing Activities:
Purchase of Fixed Assets and Leasehold Improvements	(5,120)			(100,792)
Net Cash Used In Investing Activities	(5,120)			(100,792)
Cash Flows From Financing Activities:
Proceeds from notes payable - related party		550,000	1,015,000	320,000
Proceeds from convertible note payable, net of original issue discount	3,670,000		950,000
Payment of debt offering costs			(86,000)
Principal payments on debt	(25,000)	(30,000)	(40,000)	(20,000)
Proceeds from warrant exercise	177,558
Contributed capital - related party		17,495	17,495
Proceeds from SBA Paycheck Protection Loan		90,100	90,100
Proceeds from issuance of common stock				1,000,000
Net Cash Provided by Financing Activities	3,822,558	627,595	1,946,595	1,300,000
Net Increase in Cash	2,850,633	(70,314)	691,883	111,327
Cash at Beginning of Period	816,907	125,024	125,024	13,697
Cash at End of Period	3,667,540	54,710	816,907	125,024
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Shares issued in connection with cashless warrants exercise	292,533		365,157	329,622
Beneficial conversion feature in connection with convertible debt	3,670,000		864,000
Original issue discount in connection with convertible debt			50,000
Settlement of accounts payable with note payable				265,244
Settlement of accounts payable with stock issuance				281,659
Adoption of lease standard ASC 842	79,862			$ 559,568
Cancellation and forgiveness of lease - related party	$ 44,419

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations. It is management’s opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date. Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents as of June 30, Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For June 30, The computation of basic and diluted loss per share for June 30, SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE June 30, 2021 December 31, 2020 Antidilutive Securities 114,490,727 76,460,919 Stock Warrants (Exercise price - $ 0.001 0.25 53,911,463 49,120,917 Stock Options (Exercise price - $ 0.1150 26,802,500 27,340,000 Convertible Debt 33,776,762 - Convertible Preferred Stock 2 2 Total 114,490,727 76,460,919 Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation. Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07. Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU include removing exceptions to incremental intraperiod tax allocation of losses and gains from different financial statement components, exceptions to the method of recognizing income taxes on interim period losses, and exceptions to deferred tax liability recognition related to foreign subsidiary investments. In addition, the ASU requires that entities recognize franchise tax based on an incremental method and requires an entity to evaluate the accounting for step-ups in the tax basis of goodwill as inside or outside of a business combination. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The ASU is currently not expected to have a material impact on our financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies the accounting for convertible instruments by removing certain separation models in ASC 470- 20, Debt—Debt with Conversion and Other Options, for convertible instruments. The ASU updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835, Interest. Further, the ASU made amendments to the EPS guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU also made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. The amendments to Topic 815-40 change the scope of contracts that are recognized as assets or liabilities. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for periods beginning after December 15, 2020. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. The ASU is currently not expected to have a material impact on our financial statements. Recently Adopted Accounting Standards In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, to require financial assets carried at amortized cost to be presented at the net amount expected to be collected based on historical experience, current conditions, and forecasts. Subsequently, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU No. 2019-04, ASU No. 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-02, and ASU 2020-03 to provide additional guidance on the credit losses standard. Adoption of the ASUs is on a modified retrospective basis. We adopted the ASUs on January 1, 2020. The ASUs did not have a material impact on our consolidated financial statements. ASU No. 2016-13 applies to all financial assets including loans, trade receivables and any other financial assets not excluded from the scope that have the contractual right to receive cash. The adoption of this ASU did not have any impact on our financial statements. Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no impairment losses recorded for the six June 30, Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at June 30, ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS June 30, 2021 December 31, 2020 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ - Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017 and ending in September 2018, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the three and six June 30, 0 and $ 0 respectively in revenue. On January 25, 2021, the Company signed an amendment to a strategic partnership agreement with Kings Group for and exclusive sales agreement for up to $40 million. On April 8, 2021, the Company and Kings Group formed Spydasilk Enterprises Pte. Ltd., a Singapore company, to formalize this partnership. Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At June 30, 3,224,000 and $ 500,000 , respectively in excess of FDIC insurance limits. For the six June 30, 0 0 Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to interest expense in the consolidated statements of operations over the life of the debt. Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument. Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION Organization Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date. Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2020 and December 31, 2019, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2020 and 2019 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2020 December 31, 2019 Stock Warrants (Exercise price - $ 0.001 0.16 49,120,917 57,995,917 Stock Options (Exercise price - $ 0.1150 27,340,000 - Convertible Preferred Stock 2 2 Total 76,460,919 57,995,919 Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation. Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2020 2019 Expected income tax (recovery) expense at the statutory rate of 21 $ (1,043,948 ) $ (610,845 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 608,152 142,167 Change in valuation allowance 435,795 468,678 Provision for income taxes $ - $ - The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES Years Ended December, 2020 2019 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 3,815,336 3,379,542 Valuation allowance (3,815,336 ) (3,379,542 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2040. The net change in the valuation allowance for the year ended December 31, 2020 and 2019 was an increase of $ 435,795 610,845 Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07. Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU include removing exceptions to incremental intraperiod tax allocation of losses and gains from different financial statement components, exceptions to the method of recognizing income taxes on interim period losses, and exceptions to deferred tax liability recognition related to foreign subsidiary investments. In addition, the ASU requires that entities recognize franchise tax based on an incremental method and requires an entity to evaluate the accounting for step-ups in the tax basis of goodwill as inside or outside of a business combination. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. We have not early adopted this ASU as of December 31, 2020. The ASU is currently not expected to have a material impact on our financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies the accounting for convertible instruments by removing certain separation models in ASC 470- 20, Debt—Debt with Conversion and Other Options, for convertible instruments. The ASU updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835, Interest. Further, the ASU made amendments to the EPS guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU also made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. The amendments to Topic 815-40 change the scope of contracts that are recognized as assets or liabilities. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for periods beginning after December 15, 2020. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. The ASU is currently not expected to have a material impact on our financial statements. Recently Adopted Accounting Standards In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, to require financial assets carried at amortized cost to be presented at the net amount expected to be collected based on historical experience, current conditions, and forecasts. Subsequently, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU No. 2019-04, ASU No. 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-02, and ASU 2020-03 to provide additional guidance on the credit losses standard. Adoption of the ASUs is on a modified retrospective basis. We adopted the ASUs on January 1, 2020. The ASUs did not have a material impact on our consolidated financial statements. ASU No. 2016-13 applies to all financial assets including loans, trade receivables and any other financial assets not excluded from the scope that have the contractual right to receive cash. The adoption of this ASU did not have any impact on our financial statements. Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2020 and 2019. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2020 December 31, 2019 Level 1 $ $ Level 2 $ - $ - Level 3 $ - $ - Total $ - $ - Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the years ended December 31, 2020 and 2019, the Company recognized $0 and $0 respectively in revenue from the Government contract. These revenues were generated for work performed in the development and production of the Company’s recombinant silks under the base and option period phases of our ongoing contract with the US Army. On July 24, 2017, the Company signed a contract option extension with the US Army to research and deliver recombinant spider silk fibers and threads. This contract option increased the total contract award by an additional $ 921,130 1,021,092 Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2020 and December 31, 2019, the Company had approximately $ 500 0 For the years ended December 31, 2020 and 2019, the Company booked $ 0 0 Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to interest expense in the consolidated statements of operations over the life of the debt. Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument. Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt

GOING CONCERN

GOING CONCERN	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 GOING CONCERN As reflected in the accompanying condensed unaudited financial statements, the Company has a working capital deficiency of $ 5,082,824 and stockholders’ deficiency of $ 5,015,105 and used $ 966,805 of cash in operations for the six June 30, Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.	NOTE 2 GOING CONCERN As reflected in the accompanying financial statements, the Company has a working capital deficiency of $ 6,631,299 6,573,564 1,254,712 Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

EQUIPMENT

EQUIPMENT	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
EQUIPMENT	NOTE 3 EQUIPMENT At June 30, 2021 and December 31, 2020, property and equipment, net, is as follows: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2021 December 31, 2020 Automobile $ 41,805 $ 41,805 Laboratory Equipment 101,656 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 85,389 85,389 Less: Accumulated Depreciation (155,189 ) (141,743 ) Total Property and Equipment, net $ 80,921 $ 89,247 Depreciation expense for the six months June 30, 2021 and 2020, was $ 13,446 and $ 13,118 , respectively. Depreciation expense for the three months ended June 30, 2021 and 2020, was $ 6,778 and $ 5,740 , respectively.	NOTE 3 EQUIPMENT At December 31, 2020 and December 31, 2019, property and equipment, net, is as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2020 December 31, 2019 Automobile $ 41,805 $ 41,805 Laboratory Equipment 96,536 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 85,389 85,389 Less: Accumulated Depreciation (141,743 ) (113,669 ) Total Property and Equipment, net $ 89,247 $ 117,321 Depreciation expense for the years ended December 31, 2020 and 2019, was $ 28,074 30,781

RIGHT TO USE ASSETS AND LEASE L

RIGHT TO USE ASSETS AND LEASE LIABILITITY	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Right To Use Assets And Lease Liabilitity
RIGHT TO USE ASSETS AND LEASE LIABILITITY	NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITITY Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On January 23, 2017 the Company signed an 8 year 960 . Rent expense – related party for the six months June 30, 3,683 and $ 6,263 , respectively (See Note 9). On April 5, 2021, the Company ended this lease agreement with its President and the company removed the associated ROU asset and lease liability of $44,419. On September 5, 2019, we signed a two-year lease for a 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters. We pay an annual rent of $ 42,000 for year one of the lease and will pay $ 44,800 for year two of the lease. On April 16, 2021, the Company signed a two year amendment to this lease. Commencing on July 1, 2021 and ending on September 30, 2022, the Company will pay an annualized rent of $ 42,000 . From October 1, 2022 through September 30, 2023, the Company will pay an annual rent of $ 44,800 . The Company recorded ROU asset of $ 79,862 and lease liability of $ 79,862 in accordance with the adoption of the new guidance. On May 9, 2019 the Company signed a 5 year property lease with the Socialist Republic of Vietnam which consists of 4,560.57 45,150 5% Right to use assets is summarized below: SCHEDULE OF RIGHT USE OF ASSETS June 30, 2021 Right to use assets, net 90,914 Right to use assets, net 241,800 Total $ 332,214 During the six June 30, $87,874 Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY June 30, 2021 Operating lease liability, net 90,223 Operating lease liability, net 254,462 Total 344,685 Less: short term portion (115,995 ) Long term position $ 228,690 Lease expense for the six months ended June 30, 2021 was comprised of the following: SCHEDULE OF LEASE COST Operating lease expense $ 17,896 Operating lease expense $ 66,295 Operating lease expense – related party $ 3,683	NOTE 4 - RIGHT TO USE ASSETS AND LEASE LIABILITITY Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On January 23, 2017 the Company signed an 8 year 960 13,092 14,793 On September 13, 2017, the Company signed a new two year 39,200 42,000 On September 5, 2019, we signed a new two-year 5,000 42,000 44,800 On May 9, 2019 the Company signed a 5 year 4,560.57 45,150 5 In February 2016, the FASB issued ASU 2016-02, “Leases” Topic 842, which amends the guidance in former ASC Topic 840, Leases The Company adopted the new lease guidance effective January 1, 2019 using the modified retrospective transition approach, applying the new standard to all of its leases existing at the date of initial application which is the effective date of adoption. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. We elected the package of practical expedients which permits us to not reassess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases, and (3) any initial direct costs for any existing leases as of the effective date. We did not elect the hindsight practical expedient which permits entities to use hindsight in determining the lease term and assessing impairment. The adoption of the lease standard did not change our previously reported consolidated statements of operations and did not result in a cumulative catch-up adjustment to opening equity. The adoption of the new guidance resulted in the recognition of ROU assets of $ 529,135 531,462 The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. In calculating the present value of the lease payments, the Company elected to utilize its incremental borrowing rate based on the remaining lease terms as of the January 1, 2019 adoption date. This rate was determined to be 8 559,568 Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred, if any. The Company has elected the practical expedient to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, current operating lease liabilities and non-current operating lease liabilities. The new standard also provides practical expedients and certain exemptions for an entity’s ongoing accounting. We have elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases where the initial lease term is one year or less or for which the ROU asset at inception is deemed immaterial, we will not recognize ROU assets or lease liabilities. Those leases are expensed on a straight line basis over the term of the lease Right to use assets is summarized below: SCHEDULE OF RIGHT USE OF ASSETS December 31, Right to use assets, net – related party $ 44,849 Right to use assets, net 41,138 Right to use assets, net 279,038 Total $ 365,025 During the years ended December 31, 2020, the Company recorded $ 98,888 Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY December 31, Right to use liability, net – related party 47,418 Right to use liability, net 42,918 Right to use liability, net 289,385 Total 379,720 Less: short term portion $ (124,909 ) Long term position $ 254,811 Lease expense for the years ended December 31, 2020 was comprised of the following: SCHEDULE OF LEASE COST Operating lease expense $ 49,505 Operating lease expense $ 36,291 Operating lease expense – related party $ 13,092

ACCRUED INTEREST _ RELATED PART

ACCRUED INTEREST – RELATED PARTY	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accrued Interest Related Party
ACCRUED INTEREST – RELATED PARTY	NOTE 5 ACCRUED INTEREST – RELATED PARTY On June 6, 2016, the Company received a $ 50,000 loan from our principal stockholder. Subsequently on December 1, 2017, the Company received an additional $ 30,000 loan from the same stockholder. On January 8, 2018 and March 31, 2018 the Company received an additional loan of $ 100,000 and $ 15,000 , respectively. The Company received additional loan funds from the same stockholder as follows: $ 20,000 on April 26, 2018; $ 15,000 on June 21, 2018; $ 15,000 on June 29, 2018; $ 20,000 on July 5, 2018; $ 26,000 on October 1, 2018; $ 11,000 on October 12, 2018; $ 20,000 on December 21, 2018; $ 3,000 on January 4, 2019; $ 30,000 on January 17, 2019; $ 30,000 on February 1, 2019; $ 20,000 on February 15, 2019; $ 20,000 on March 1, 2019; $ 17,000 on January 4, 2019, $ 100,000 on November 20, 2019, $ 100,000 on December 18, 2019, $ 100,000 on January 24, 2020, $ 100,000 on February 19, 2020 $ 100,000 on March 9, 2020, $ 100,000 on April 8, 2020, $ 150,000 on June 3, 2020, $ 100,000 on July 16, 2020, $ 100,000 on August 12, 2020,$ 100,000 on September 10, 2020, $ 30,000 on October 19, 2020, $ 30,000 on November 4, 2020, $ 35,000 on November 17, 2020 and $ 70,000 on December 1, 2020. Pursuant to the terms of the loan, the advance bears an interest at 3% , is unsecured, and due on demand. Total loan payable to principal stockholder for as of December 31, 2020 is $ 1,657,000 . Total loan payable to this principal stockholder as of June 30, 1,657,000 . During the six June 30, 41,085 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $ 26,662 . During the six June 30, 21,972 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $ 14,161 .	NOTE 5 ACCRUED INTEREST – RELATED PARTY On June 6, 2016, the Company received a $ 50,000 30,000 100,000 15,000 20,000 15,000 15,000 20,000 26,000 11,000 20,000 3,000 30,000 30,000 20,000 20,000 17,000 100,000 100,000 100,000 100,000 100,000 100,000 150,000 100,000 100,000 100,000 30,000 30,000 35,000 70,000 3 642,000 1,657,000 50,763 36,562 22,337 15,581

NOTE PAYABLE

NOTE PAYABLE	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
NOTE PAYABLE	NOTE 6 NOTE PAYABLE On March 1, 2019, the Company entered into an unsecured promissory note with Notre Dame - an unrelated party in the amount of $ 265,244 in exchange for outstanding account payable due to the debtor. Pursuant to the terms of the note, the note bears 10% interest per year from the date of default until the date the loan is paid in full. The term of the loan is twenty four months six June 30, 25,000 of the loan balance (See Note 8 (A)): 1. $ 1,000 2. $ 2,000 3. $ 5,000 4. Final payment of all remaining balance, in the amount of $ 180,224 On April 16, 2020, the Company, was granted a loan (the “Loan”) from The Huntington National Bank, in the aggregate amount of $ 90,100 April 16, 2022 1% 100% 90,100	NOTE 6 NOTE PAYABLE On March 1, 2019, the Company entered into an unsecured promissory note with Notre Dame - an unrelated party in the amount of $ 265,244 10 twenty four months 40,000 1. $ 1,000 2. $ 2,000 3. $ 5,000 4. Final payment of all remaining balance, in the amount of $ 180,224 On April 16, 2020, the Company, was granted a loan (the “Loan”) from The Huntington National Bank, in the aggregate amount of $ 90,100 The Loan, which was in the form of a Note dated on or about April 16, 2020 issued by the Borrower, matures on or about April 16, 2022 1

CONVERTIBLE NOTES

CONVERTIBLE NOTES	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Convertible Notes
CONVERTIBLE NOTES	NOTE 7 CONVERTIBLE NOTES The Company issued a $ 1,000,000 January 11, 2022 10% 5 50,000 950,000 The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date Additionally, the Company issued 3,125,000 5 2,599,066 SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $ 1,000,000 The Company also paid $ 86,000 On March 25, 2021, the Company entered into one year, unsecured, convertible note in the aggregate principal amount of $ 4,000,000 for which the first convertible debenture for $ 500,000 , a one year , unsecured, convertible note on March 25, 2021, which is due March 25, 2022 . The convertible note bears interest at 10 500,000 was issued on April 6, 2021 and the third convertible debenture of $ 3,000,000 was issued on April 22, 2021. Additionally, the Company issued 8,000,000 5 3,359,716 Stock Price $ 0.15 Exercise price $ 0.25 Expected term (in years) 5 Expected volatility 100.76 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.07 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $ 3,000,000 , and was recorded on the commitment date. The discount is amortized to amortization of debt discount over the life of the underlying convertible note. The Company also paid $ 330,000 as a debt issuance cost to a placement agent for services rendered. These costs are a component of the total debt discount. On April 23, 2021, the Company issued 836,574 shares of Common Stock in exchange for conversion of $ 100,000 of principle balance on a convertible debenture and $ 1,644 of accrued interest (See Note 9). On April 26, 2021, the Company issued 2,063,391 shares of Common Stock in exchange for conversion of $ 250,000 of principle balance on a convertible debenture and $ 3,178 of accrued interest (See Note 9). On April 30, 2021, the Company issued 2,058,686 shares of Common Stock in exchange for conversion of $ 250,000 of principle balance on a convertible debenture and $ 3,630 of accrued interest. The shares had a fair value of $ 338,654 (See Note 9). On June 7, 2021, the Company issued 2,431,506 shares of Common Stock in exchange for conversion of $ 200,000 of principle balance on a convertible debenture and $ 25,644 of accrued interest (See Note 9). On June 23, 2021, the Company issued 2,422,195 shares of Common Stock in exchange for conversion of $ 200,000 of principle balance on a convertible debenture and $ 10,247 of accrued interest (See Note 9). SUMMARY OF CONVERTIBLE DEBT The following represents a summary of the Company’s convertible debt at June 30, Convertible Note Payable Amounts In-Default Balance – December 31, 2020 50,505 - Proceeds – net 4,000,000 - Debt discount recorded (5,000,000 ) - Amortization of debt discount 2,084,468 - Balance – June 30, $ 1,134,973 $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2020 5,479 - Interest Expense June 30, 119,096 - Interest conversion into common shares (44,342 ) Balance – June 30, $ 80,233 $ -	NOTE 7 CONVERTIBLE NOTE S The Company issued a $ 1,000,000 thirteen-month January 11, 2022 10% 5% 50,000 950,000 The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date Additionally, the Company issued 3,125,000 5 2,599,066 SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 % The Company has determined that ASC 815 does not apply since the Company has unlimited authorized shares, which in turn satisfies the requirement of having sufficient authorized shares available to settle any potential instruments that may require physical net-share settlement. Pursuant to ASC 470, the Company will record a beneficial conversion feature (“BCF”) based upon the relative fair value of the conversion feature within the convertible note and the related warrants. The BCF cannot exceed the face amount of the note, therefore, the discount for this note is $ 1,000,000 The Company also paid $ 86,000 The following represents a summary of the Company’s convertible debt at December 31, 2020: SUMMARY OF CONVERTIBLE DEBT Convertible Note Payable Amounts In-Default Balance – December 31, 2019 - Proceeds – net 950,000 - Original issue discount 50,000 - Debt discount recorded (1,000,000 ) - Amortization of debt discount 50,505 - Balance – December 31, 2020 $ 50,505 $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2019 - Interest Expense 2020 5,479 Balance – December 31, 2020 $ 5,479 $ -

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 STOCKHOLDERS’ DEFICIT (A) Common Stock Issued for Cash On March 9, 2019, the Company entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 0.06758 1,000,000 14,797,278 14,797,278 0.06 7,398,639 0.08 ● ½ of all $ 0.06 March 8, 2021 ● ½ of all $ 0.06 March 8, 2022 ● ½ of all $ 0.08 March 8, 2022 ● ½ of all $ 0.08 March 8, 2023 On March 2, 2021, the Company determined to amend and extend the expiration of the warrants expiring on March 8, 2021 as follows: ● 1,479,728 0.06 March 8, 2021 ● 1,479,728 0.06 May 8, 2021 ● 1,479,728 0.06 July 8, 2021 ● 1,479,728 0.06 September 8, 2021 ● 1,479,727 0.06 November 8, 2021 On March 2, 2021, the Company issued 1,479,728 88,784 On May 4, 2021, the Company issued 1,479,728 shares of Common stock in connection with the exercise of 1,479,728 warrants for $ 88,784 (See Note 8 (C)). (B) Common Stock Issued for Services Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant. On March 20, 2019, the Company issued 4,052,652 281,659 0.0695 243,159 38,500 (C) Common Stock Warrants and Options On March 5, 2021, the Company issued 786,280 2,000,000 On March 2, 2021, the Company issued 1,479,728 shares of Common stock in connection with the exercise of 1,479,728 warrants for $88,784 (See Note 8 (A)). On May 4, 2021, the Company issued 1,479,728 shares of Common stock in connection with the exercise of 1,479,728 warrants for $88,784 (See Note 8 (A)). On February 24, 2021, the Company issued 70,786 200,000 On July 30, 2020, the Company issued 9,941,623 10,000,000 SCHEDULE OF OPTION ASSUMPTION On April 27, 2021, the Company extended the expiration date of the warrant issued on October 2, 2016 to October 1, 2026. During the six months ended June 30, 2021 the Company recorded an additional $ 217,715 as an expense for the warrant extension. Expected dividends 0 % Expected volatility 158.54 % Expected term 3 Risk free interest rate 1.37 % Expected forfeitures 0 % On February 2, 2021, the Company extended the expiration date of the warrant to May 29, 2026. During the six months ended June 30, 2021 the Company recorded an additional $ 85 as an expense for the warrant extension. Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % On January 1, 2016, the Company issued 3-year warrant to purchase 6,000,000 shares of common stock at $ 0.001 per share to a related party for services to be rendered. The warrants had a fair value of $ 142,526 , based upon the Black-Scholes option-pricing model on the date of grant and vested on February 20, 2017, and will be exercisable commencing on February 20, 2018, and for a period expiring on February 20, 2021. On February 2, 2021, the Company extended the expiration date of the warrant to May 29, 2026. During the six June 30, 85 as an expense for the warrant extension. Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % On January 25, 2021, the Company issued a 7-year option to purchase 2,500,000 shares of common stock at an exercise price of $ 0.134 per share to a related party for services rendered. The options had a fair value of $ 310,165 , based upon the Black-Scholes option-pricing model on the date of grant. Options vest 33.3% on the year one anniversary of the grant date, 33.3% will vest on the second anniversary, and 33.3% will vest on the third year anniversary as long as the employee remains with the Company. at the end of each successive year for three years. Options will be exercisable on January 25, 2021, and for a period of 7 years expiring on January 25, 2028. During the six June 30, 41,009 as an expense for options issued. Expected dividends 0 % Expected volatility 133.22 % Expected term 7 Risk free interest rate 1.46 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 10-year option to purchase 6,000,000 shares of common stock at an exercise price of $ 0.115 per share to a related party for services rendered. The options had a fair value of $ 626,047 , based upon the Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030. During the six June 30, $ 51,706 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 7-year option to purchase 1,340,000 shares of common stock at an exercise price of $ 0.115 per share to employees for services rendered. The options had a fair value of $ 133,063 , based upon the Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027. During the six June 30, 15,771 as an expense for options issued, net of $ 20,853 for the 800,000 options cancelled due to termination of employment. Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3-year option to purchase 2,000,000 shares of common stock at an exercise price of $ 0.2299 per share to a related party for services rendered. The options had a fair value of $ 291,842 , based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the six June 30, 72,262 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 0.2299 18,240 Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. 9,133 12,751 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 0.2299 19,525 Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027. 6,520 9,103 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Weighted Balance, December 31, 2020 49,120,917 - 1.83 Granted 8,000,000 - - Exercised (2,959,456 ) - - Cancelled/Forfeited (250,000 ) - - Balance, June 30, 53,911,461 - 2.77 Intrinsic Value $ 2,895,566 For the six months ended June 30, 2021, the following warrants were outstanding: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.57 $ 1,311,000 $ 0.056 2,000,000 0.11 $ 128,000 $ 0.04 2,300,000 5.26 $ 184,000 $ 0.06 4,439,184 0.33 $ 532,702 $ 0.06 7,398,639 0.68 $ 443,918 $ 0.08 3,699,320 0.68 $ 147,973 $ 0.08 3,699,320 1.68 $ 147,973 $ 0.2299 8,250,000 3.72 $ - $ 0.16 3,125,000 4.45 $ - $ 0.25 8,000,000 4.73 $ - For the year ended December 31, 2020, the following warrants were outstanding: Exercise Price Warrants Exercisable Weighted Average Remaining Aggregate $ 0.001 11,000,000 1.19 $ 1,371,500 $ 0.056 2,000,000 0.60 $ 139,000 $ 0.04 2,300,000 0.65 $ 196,650 $ 0.06 7,398,639 0.18 $ 484,611 $ 0.06 7,398,639 1.18 $ 484,611 $ 0.08 3,699,320 1.18 $ 168,319 $ 0.08 3,699,320 2.18 $ 168,319 $ 0.2299 8,500,000 4.27 $ - $ 0.16 3,125,000 4.95 $ - For the six June 30, SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 26,802,500 19.62 For the year ended December 31, 2020, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 22,267,800 22.6 (D) Amendment to Articles of Incorporation On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows: ● Common stock Class A, unlimited number of shares authorized, no par value ● Common stock Class B, unlimited number of shares authorized, no par value ● Preferred stock, unlimited number of shares authorized, no par value Effective December 17, 2013, the Company amended its articles of incorporation to designate a Series A no par value preferred stock. Two shares of Series A Preferred stock have been authorized. (E) Common Stock Issued for Debt On April 23, 2021, the Company issued 836,574 shares of Common Stock in exchange for conversion of $ 100,000 of principle balance on a convertible debenture and $1,644 of accrued interest (See Note 7). On April 26, 2021, the Company issued 2,063,391 shares of Common Stock in exchange for conversion of $ 250,000 of principle balance on a convertible debenture and $ 3,178 of accrued interest (See Note 7). On April 30, 2021, the Company issued 2,058,686 shares of Common Stock in exchange for conversion of $ 250,000 of principle balance on a convertible debenture and $3,630 of accrued interest (See Note 7). On June 7, 2021, the Company issued 2,431,506 shares of Common Stock in exchange for conversion of $ 200,000 of principle balance on a convertible debenture and $ 25,644 of accrued interest. The shares had a fair value of $ 297,373 . The Company recorded a loss on debt settlement of $ 71,729 (See Note 7). On June 23, 2021, the Company issued 2,422,195 shares of Common Stock in exchange for conversion of $ 200,000 of principle balance on a convertible debenture and $10,247 of accrued interest (See Note 7).	NOTE 8 STOCKHOLDERS’ DEFICIT (A) Common Stock Issued for Cash On March 9, 2019, the Company entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 0.06758 1,000,000 14,797,278 14,797,278 0.06 7,398,639 0.08 ● ½ of all $ 0.06 March 8, 2021 ● ½ of all $ 0.06 March 8, 2022 ● ½ of all $ 0.08 March 8, 2022 ● ½ of all $ 0.08 March 8, 2023 (B) Common Stock Issued for Services Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant. On March 20, 2019, the Company issued 4,052,652 281,659 0.0695 243,159 38,500 (C) Common Stock Warrants and Options On July 30, 2020, the Company issued 9,941,623 10,000,000 On February 19, 2020 the Company issued a 20 20,000,000 0.115 2,198,411 Options will be exercisable on February 19, 2025, and for a period of 15 years expiring on February 19, 2040 2,198,411 SCHEDULE OF OPTION ASSUMPTION Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.56 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 10 6,000,000 0.115 626,047 Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030 272,673 Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 7 1,340,000 0.115 133,063 Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027 40,935 Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 % On September 26, 2019, the Company issued 766,667 1,000,000 7,967,871 8,000,000 On August 8, 2019, the Company issued a 2 2,000,000 0.2299 267,574 Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024 267,574 Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2 2,000,000 0.2299 267,574 Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025 161,568 Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3 2,000,000 0.2299 291,842 Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026 146,121 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2 1,000,000 0.2299 118,874 Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023 118,874 Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2 1,000,000 0.2299 118,874 Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024 118,874 Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2 125,000 0.2299 14,859 Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023 14,859 Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2 125,000 0.2299 16,723 Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025 10,098 Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2 125,000 0.2299 18,240 Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026 9,133 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2 125,000 0.2299 19,525 Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027 6,520 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On March 20, 2018, the Company issued a 4 600,000 0.001 19,915 Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022 19,915 600,000 6,000 Expected dividends 0 % Expected volatility 97.56 % Expected term 4 Risk free interest rate 2.65 % Expected forfeitures 0 % On September 26, 2019, the Company issued 766,667 1,000,000 On August 14, 2019, the Company issued 7,967,871 8,000,000 SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Exercise Price Weighted Balance, December 31, 2019 55,995,917 - 2.77 Granted 3,125,000 - - Exercised (10,000,000 ) - - Cancelled/Forfeited - - - Balance, December 31, 2020 49,120,917 - 1.83 Intrinsic Value $ 3,013,010 For the year ended December 31, 2020, the following warrants were outstanding: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 1.19 $ 1,371,500 $ 0.056 2,000,000 0.60 $ 139,000 $ 0.04 2,300,000 0.65 $ 196,650 $ 0.06 7,398,639 0.18 $ 484,611 $ 0.06 7,398,639 1.18 $ 484,611 $ 0.08 3,699,320 1.18 $ 168,319 $ 0.08 3,699,320 2.18 $ 168,319 $ 0.2299 8,500,000 4.27 $ - $ 0.16 3,125,000 4.95 $ - For the year ended December 31, 2019, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 21,000,000 1.65 $ 4,069,800 $ 0.056 3,000,000 1.61 $ 387,600 $ 0.04 2,300,000 1.70 $ 445,740 $ 0.06 7,398,639 1.19 $ 1,433,856 $ 0.06 7,398,639 2.19 $ 1,433,856 $ 0.08 3,699,320 2.19 $ 716,928 $ 0.08 3,699,320 3.19 $ 719,928 $ 0.2299 8,500,000 5.39 $ 1,647,300 For the year ended December 31, 2020, the following options were outstanding: SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 22,267,800 22.6 (D) Amendment to Articles of Incorporation On February 16, 2009, the Company amended its articles of incorporation to amend the number and class of shares the Company is authorized to issue as follows: ● Common stock Class A, unlimited no ● Common stock Class B, unlimited no ● Preferred stock, unlimited no Effective December 17, 2013, the Company amended its articles of incorporation to designate a Series A no Two (E) Common Stock Issued for Debt None (F) Capital contribution – Related Party For the year ended December 31, 2020, the Company recorded $ 17,495

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 COMMITMENTS AND CONTINGENCIES On November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31, 2015. The term of the agreement is a five year period at an annual salary of $ 210,000 . There is a 6 % annual increase. For the year ending December 31, 2015, the annual salary was $ 281,027 . The employee is also to receive a 20 5 years 297,889 5 years 315,764 5 years 398,643 for the year ended December 31, 2021. As of June 30, 2,924,436 and $ 2,804,725 , respectively (See Note 10). On January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to an annual cash compensation of $ 120,000 11,000 2,000,000 0.001 three-year 3,000,000 0.001 May 28, 2022 121,448 140,000 three-year 6,000,000 0.001 May 20, 2026 the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. 6,000,000 0.2299 20,000 20,000 20,000 ● The Company maintaining $ 6,000,000 ● Upon the transfer of ownership of more than 50 ● Upon the fifth year anniversary of the salary increase and the bonus issuance. As of June 30, $ 29,943 and $ 103,730 , respectively, to Mr. Rice for payroll payable. On October 21, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $ 20,000 ● The Company maintaining $ 6,000,000 ● Upon the transfer of ownership of more than 50 ● Upon the fifth year anniversary of the salary increase and the bonus issuance. On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to annual cash compensation of $ 60,000 . In addition, Mr. Le was issued two three-year warrants to purchase 2,000,000 shares of common stock of the Company at an exercise price of $ 0.2299 per share. As of June 30, $ 3,018 and $ 888 , respectively. (A) License Agreement On May 8, 2006, the Company entered into a license agreement. Pursuant to the terms of the agreement, the Company paid a non- refundable license fee of $ 10,000 10,000 13,700 10,000 On October 28, 2011, the Company entered into a license agreement with the University of Notre Dame. Under the agreement, the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. In consideration of the licenses granted under the agreement, the Company agreed to issue to the University of Notre Dame 2,200,000 shares of its common stock and to pay a royalty of 2 20 years 5,000 4 years On May 5, 2017, the Company signed an addendum to that agreement relating to tangible property and project intellectual property. On March 1, 2019, the Company singed an addendum to that agreement. The Company entered into a separate loan agreement and promissory noted dated March 1, 2019 as a payment for expenses paid by the University prior to January 31, 2019 totaling $ 265,244 and issued 4,025,652 shares of Class A common stock with a fair value of $ 281,659 as payment of certain debt. In the event of default the license agreement will be terminated. During the six June 30, $ 25,000 of the balance (See Notes 6). On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, 120,000 that was due on December 26, 2007. As of June 30, 65,292 . For the six June 30, 490 in interest expensed and related accrued interest payable. As of June 30, $ 9,483 . On December 30, 2015, the Company entered into a cooperative agreement for the research and pilot production of hybrid silkworms in Vietnam. Under this agreement, the Company will establish a subsidiary in Vietnam where it will develop and produce hybrid silkworms. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. (B) Operating Lease Agreements Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On May 9, 2019 the Company signed a 5 4,560.57 45,150 On January 23, 2017 the Company signed an 8 960 . Rent expense – related party for the six June 30, $ 3,683 and $ 6,263 , respectively (See Note 10). On April 5, 2021, the Company ended this lease agreement with its President. On September 13, 2017, the Company signed a new two year lease with a 2 year option September 31, 2019. paid 39,200 for the year one of lease and $ 42,000 for the year two of lease for office and manufacturing space. On September 5, 2019, the Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters. The Company pays an annual rent of $ 42,000 for year one of the lease and $ 44,800 for year two of the lease. On April 16, 2021, the Company signed a two year amendment to this lease. Commencing on July 1, 2021 and ending on September 30, 2022, the Company will pay an annualized rent of $42,000. From October 1, 2022 through September 30, 2023, the Company will pay an annual rent of $44,800.	NOTE 9 COMMITMENTS AND CONTINGENCIES On November 10, 2010, the Company entered into an employment agreement with its CEO, effective January 1, 2011 through the December 31, 2015. The term of the agreement is a five year 210,000 6% 281,027 20% 5 years 297,889 5 years 315,764 5 years 354,791 5 years 376,078 2,804,725 2,535,203 On January 20, 2015, the board of directors appointed Mr. Jonathan R. Rice as our Chief Operating Officer. Mr. Rice’s employment agreement has a term of one year 120,000 11,000 three 2,000,000 0.001 three-year 3,000,000 0.001 May 28, 2022 121,448 one year 140,000 three 6,000,000 0.001 May 20, 2026 the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019. three five 6,000,000 0.2299 20,000 20,000 20,000 ●The Company maintaining $ 6,000,000 ●Upon the transfer of ownership of more than 50% ●Upon the fifth year anniversary of the salary increase and the bonus issuance. As of December 31, 2020 and December 31, 2019 the Company owes $ 103,730 64,352 On October 21, 2019, the Company signed an agreement to increase Mr. Rice’s base salary by $ 20,000 ●The Company maintaining $ 6,000,000 ●Upon the transfer of ownership of more than 50% ●Upon the fifth year anniversary of the salary increase and the bonus issuance. On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year 60,000 three 2,000,000 0.2299 888 1,154 (A) License Agreement On May 8, 2006, the Company entered into a license agreement. Pursuant to the terms of the agreement, the Company paid a non- refundable license fee of $ 10,000 10,000 13,700 10,000 On October 28, 2011, the Company entered into a license agreement with the University of Notre Dame. Under the agreement, the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. In consideration of the licenses granted under the agreement, the Company agreed to issue to the University of Notre Dame 2,200,000 2% 20 years The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years. 265,244 4,025,652 281,659 40,000 On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. In accordance with FASB ASC No 480, Distinguishing Liabilities from Equity, 120,000 December 26, 2007 65,292 2,623 1,960 8,503 On December 30, 2015, the Company entered into a cooperative agreement for the research and pilot production of hybrid silkworms in Vietnam. Under this agreement, the Company will establish a subsidiary in Vietnam where it will develop and produce hybrid silkworms. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. (B) Consulting Agreement On February 20, 2018, the Company signed an agreement with a consultant to provide services. Under this agreement the consultant will receive a warrant for 600,000 3,000,000 4 600,000 0.001 19,915 Warrants will be exercisable on March 20, 2019 19,915 600,000 6,000 (C) Operating Lease Agreements Since September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $ 2,508 On May 9, 2019 the Company signed a 5 4,560.57 45,150 5% On January 23, 2017 the Company signed an 8 960 9,819 11,913 On September 13, 2017, the Company signed a new two year lease commencing on October 1, 2017 and ending on March 31, 2020. The Company pays an annual rent of $ 39,200 42,000 the Company signed a new two-year 5,000 42,000 44,800

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 RELATED PARTY TRANSACTIONS On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. Pursuant to the addendum, the Company agreed to issue either 200,000 no voting rights equal to 100 common shares per share of preferred stock 120,000 , the officer agreed to terminate the royalty payments due under the agreement and give title to the exclusive license for the non-protective apparel use of the intellectual property to the Company. On the date of the agreement, the Company did not have any preferred stock authorized with the required preferences. In accordance with FASB ASC No. 480, Distinguishing Liabilities from Equity 120,000 that was due on December 26, 2007, one year June 30, 65,292 . Additionally, the accrued expenses are accruing 7 % interest per year. As of June 30, $ 9,483 . On November 10, 2010, the Company entered into an employment agreement, with its CEO, effective January 1, 2011 through the December 31, 2015. Subsequently, on January 1, 2018 the agreement renewed with the same terms for another 5 years 398,643 for the year ended December 31, 2021. As of June 30, $ 2,924,436 and $ 2,804,725 , respectively. On January 14, 2016, the Company signed a new employment agreement with Mr. Rice, the Company’s COO. The employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Rice is entitled to annual cash compensation of $ 140,000 three-year 6,000,000 0.001 the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 10, 2025 for Mr. Rice. 20,000 20,000 20,000 ● The Company maintaining $ 6,000,000 ● Upon the transfer of ownership of more than 50 ● Upon the fifth year anniversary of the salary increase and the bonus issuance. As of June 30, $ 29,943 and $ 103,730 , respectively, to Mr. Rice for payroll payable. On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year and can be terminated by either the Company or Mr. Rice at any time. Under the employment agreement, Mr. Le is entitled to an annual cash compensation of $ 60,000 . In addition, Mr. Le was issued two three-year warrants to purchase 2,000,000 shares of common stock of the Company at an exercise price of $ 0.2299 per share. As of June 30, $ 3,018 and $ 888 , respectively. June 6, 2016, the Company received a $ 50,000 loan from our principal stockholder. Subsequently on December 1, 2017, the Company received an additional $ 30,000 loan from the same stockholder. On January 8, 2018 and March 31, 2018 the Company received an additional loan of $ 100,000 and $ 15,000 , respectively. The Company received additional loan funds from the same stockholder as follows: $ 20,000 on April 26, 2018; $ 15,000 on June 21, 2018; $ 15,000 on June 29, 2018; $ 20,000 on July 5, 2018; $ 26,000 on October 1, 2018; $ 11,000 on October 12, 2018; $ 20,000 on December 21, 2018; $ 3,000 on January 4, 2019; $ 30,000 on January 17, 2019; $ 30,000 on February 1, 2019; $ 20,000 on February 15, 2019; $ 20,000 on March 1, 2019; $ 17,000 on January 4, 2019, $ 100,000 on November 20, 2019, $ 100,000 on December 18, 2019, $ 100,000 on January 24, 2020, $ 100,000 on February 19, 2020, $ 100,000 on March 9, 2020, $ 100,000 on April 8, 2020, $ 150,000 on June 3, 2020, $ 100,000 on July 16, 2020, $ 100,000 on August 12, 2020,$ 100,000 on September 10, 2020, $ 30,000 on October 19, 2020, $ 30,000 on November 4, 2020, $ 35,000 on November 17, 2020 and $ 70,000 on December 1, 2020. Pursuant to the terms of the loan, the advance bears an interest at 3 %, is unsecured, and due on demand. Total loan payable to principal stockholder for as of December 31, 2020 is $ 1,657,000 . Total loan payable to this principal stockholder as of June 30, 1,657,000 . During the six June 30, $ 41,085 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $ 26,662 . During the six months ended June 30, $ 21,972 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $ 14,161 . On January 23, 2017, the Company signed an 8 year property lease with the Company’s President for land in Texas. The Company pays $ 960 per month starting on February 1, 2017 and uses this facility to grow mulberry for its U.S. silk operations. Rent expense – related party for years ended June 30, $ 3,683 and $ 6,263 , respectively. The Company ended this lease on April 5, 2021. As of June 30, $ 338,049 and $ 331,143 , respectively, included in accounts payable and accrued expenses - related party, which is owed to the Company’s Chief Executive Officer and Chief Operations Officer. As of June 30, $ 1,732,191 of accrued interest- related party and $ 108,900 in shareholder loan interest – related party included in accounts payable and accrued expenses – related party, which is owed to the Company’s Chief Executive officer. As of December 31, 2020, there was $ 1,562,499 82,238 As of June 30, $ 2,924,436 in accrued salary to its principal stockholder, $ 29,943 to the Company’s COO, $ 3,018 to Director of Prodigy Textiles and $ 26,110 to its office employees. As of December 31, 2020, the Company owes $ 2,804,725 103,730 888 22,900 The Company owes $ 65,292 in royalty payable to related party as of June 30,	NOTE 10 RELATED PARTY TRANSACTIONS On December 26, 2006, the Company entered into an addendum to the intellectual property transfer agreement with Mr. Thompson, its CEO. Pursuant to the addendum, the Company agreed to issue either 200,000 no voting rights equal to 100 common shares per share of preferred stock 120,000 Distinguishing Liabilities from Equity 120,000 December 26, 2007 one year 65,292 7% 8,503 On November 10, 2010, the Company entered into an employment agreement, with its CEO, effective January 1, 2011 through the December 31, 2015. Subsequently, on January 1, 2018 the agreement renewed with the same terms for another 5 years 334,708 2,804,725 2,535,203 On January 14, 2016, the Company signed a new employment agreement with Mr. Rice, the Company’s COO. The employment agreement has a term of one year 140,000 three 6,000,000 0.001 the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 10, 2025 for Mr. Rice. 20,000 20,000 20,000 ● The Company maintaining $ 6,000,000 ● Upon the transfer of ownership of more than 50% ● Upon the fifth year anniversary of the salary increase and the bonus issuance. As of December 31, 2020 and December 31, 2019, the Company owes $ 103,730 64,351 On July 3, 2019, the board of directors appointed Mr. Kenneth Le as the Company’s Director of Government relations and President of Prodigy Textiles. Mr. Le’s employment agreement has a term of one year 60,000 three-year 2,000,000 0.2299 888 1,154 June 6, 2016, the Company received a $ 50,000 30,000 100,000 15,000 20,000 15,000 15,000 20,000 26,000 11,000 20,000 3,000 30,000 30,000 20,000 20,000 17,000 100,000 100,000 100,000 100,000 100,000 100,000 150,000 100,000 100,000 100,000 30,000 30,000 35,000 70,000 3% 642,000 1,657,000 50,763 36,562 22,337 15,581 On January 23, 2017, the Company signed an 8 960 13,092 14,793 As of December 31, 2020 and December 31, 2019, there was $ 331,143 304,539 As of December 31, 2020, there was $ 1,562,499 69,669 As of December 31, 2019, there was $ 1,196,503 43,715 As of December 31, 2020, the Company owes $ 2,804,725 103,730 888 22,900 As of December 31, 2019, the Company owes $ 2,535,203 64,351 1,153 4,477 The Company owes $ 65,292

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 SUBSEQUENT EVENTS The Company has analyzed its operations subsequent to August 12, On January 25, 2021, the Company issued a stock option for 2,500,000 stock option plan. The exercise price was $ 0.134 On January 25, 2021, the Company signed an amendment to a strategic partnership agreement with Kings Group for and exclusive sales agreement for up to $ 40 On March 2, 2021, the Company issued 1,479,728 88,783.68 On March 3, 2021, the Company received forgiveness for a $ 90,1000.00 On July 1, 2021, the Company signed a 5 36,000 square meter property and building, which it leases at a rate of approximately $ 9,570 per year for each of the five years. On July 2,343,919 shares of Common Stock in exchange for conversion of $ 200,000 of principle balance on a convertible debenture and $ 7,671 of accrued interest. On July 20, 1,664,823 shares of Common Stock in exchange for conversion of $ 100,000 of principle balance on a convertible debenture and $ 60,822 of accrued interest. On July 29, 3,101,546 shares of Common Stock in exchange for conversion of $ 200,000 of principle balance on a convertible debenture and $ 11,836 of accrued interest.	NOTE 11 SUBSEQUENT EVENTS The Company has analyzed its operations subsequent to March 12, 2021 through the date these financial statements were issued, and has determined that, other than disclosed below, it does not have any material subsequent events to disclose. On January 25, 2021, the Company issued a stock option for 2,500,000 stock option plan. The exercise price was $ 0.134 On January 25, 2021, the Company signed an amendment to a strategic partnership agreement with Kings Group for and exclusive sales agreement for up to $ 40 On March 2, 2021, the Company issued 1,479,728 88,783.68 On March 3, 2021, the Company received forgiveness for a $ 90,1000.00

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	(A) Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations. It is management’s opinion, however that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.
Foreign Currency	Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.	Foreign Currency The assets and liabilities of Prodigy Textiles, Co., Ltd. (the Company’s Vietnamese subsidiary) whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.
Use of Estimates	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash	Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents as of June 30,	Cash For the purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no
Loss Per Share	Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For June 30, The computation of basic and diluted loss per share for June 30, SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE June 30, 2021 December 31, 2020 Antidilutive Securities 114,490,727 76,460,919 Stock Warrants (Exercise price - $ 0.001 0.25 53,911,463 49,120,917 Stock Options (Exercise price - $ 0.1150 26,802,500 27,340,000 Convertible Debt 33,776,762 - Convertible Preferred Stock 2 2 Total 114,490,727 76,460,919	Loss Per Share Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by the Financial Accounting Standards Board (“FASB” Accounting Standards Codification (“ASC”) No. 260, “Earnings per Share.” For December 31, 2020 and December 31, 2019, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive. The computation of basic and diluted loss per share for December 31, 2020 and 2019 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2020 December 31, 2019 Stock Warrants (Exercise price - $ 0.001 0.16 49,120,917 57,995,917 Stock Options (Exercise price - $ 0.1150 27,340,000 - Convertible Preferred Stock 2 2 Total 76,460,919 57,995,919
Research and Development Costs	Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.	Research and Development Costs The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.
Income Taxes	Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.	Income Taxes The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC No. 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC No. 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2020 2019 Expected income tax (recovery) expense at the statutory rate of 21 $ (1,043,948 ) $ (610,845 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 608,152 142,167 Change in valuation allowance 435,795 468,678 Provision for income taxes $ - $ - The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES Years Ended December, 2020 2019 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 3,815,336 3,379,542 Valuation allowance (3,815,336 ) (3,379,542 ) Net deferred tax asset - - Net deferred tax liability $ - $ - The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2040. The net change in the valuation allowance for the year ended December 31, 2020 and 2019 was an increase of $ 435,795 610,845
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.	Stock-Based Compensation The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718 and, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASU 2018-07.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU include removing exceptions to incremental intraperiod tax allocation of losses and gains from different financial statement components, exceptions to the method of recognizing income taxes on interim period losses, and exceptions to deferred tax liability recognition related to foreign subsidiary investments. In addition, the ASU requires that entities recognize franchise tax based on an incremental method and requires an entity to evaluate the accounting for step-ups in the tax basis of goodwill as inside or outside of a business combination. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The ASU is currently not expected to have a material impact on our financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies the accounting for convertible instruments by removing certain separation models in ASC 470- 20, Debt—Debt with Conversion and Other Options, for convertible instruments. The ASU updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835, Interest. Further, the ASU made amendments to the EPS guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU also made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. The amendments to Topic 815-40 change the scope of contracts that are recognized as assets or liabilities. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for periods beginning after December 15, 2020. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. The ASU is currently not expected to have a material impact on our financial statements. Recently Adopted Accounting Standards In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, to require financial assets carried at amortized cost to be presented at the net amount expected to be collected based on historical experience, current conditions, and forecasts. Subsequently, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU No. 2019-04, ASU No. 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-02, and ASU 2020-03 to provide additional guidance on the credit losses standard. Adoption of the ASUs is on a modified retrospective basis. We adopted the ASUs on January 1, 2020. The ASUs did not have a material impact on our consolidated financial statements. ASU No. 2016-13 applies to all financial assets including loans, trade receivables and any other financial assets not excluded from the scope that have the contractual right to receive cash. The adoption of this ASU did not have any impact on our financial statements.	Recent Accounting Pronouncements Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU include removing exceptions to incremental intraperiod tax allocation of losses and gains from different financial statement components, exceptions to the method of recognizing income taxes on interim period losses, and exceptions to deferred tax liability recognition related to foreign subsidiary investments. In addition, the ASU requires that entities recognize franchise tax based on an incremental method and requires an entity to evaluate the accounting for step-ups in the tax basis of goodwill as inside or outside of a business combination. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. We have not early adopted this ASU as of December 31, 2020. The ASU is currently not expected to have a material impact on our financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies the accounting for convertible instruments by removing certain separation models in ASC 470- 20, Debt—Debt with Conversion and Other Options, for convertible instruments. The ASU updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835, Interest. Further, the ASU made amendments to the EPS guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU also made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. The amendments to Topic 815-40 change the scope of contracts that are recognized as assets or liabilities. The ASU is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted for periods beginning after December 15, 2020. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. The ASU is currently not expected to have a material impact on our financial statements. Recently Adopted Accounting Standards In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, to require financial assets carried at amortized cost to be presented at the net amount expected to be collected based on historical experience, current conditions, and forecasts. Subsequently, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU No. 2019-04, ASU No. 2019-05, ASU 2019-10, ASU 2019-11, ASU 2020-02, and ASU 2020-03 to provide additional guidance on the credit losses standard. Adoption of the ASUs is on a modified retrospective basis. We adopted the ASUs on January 1, 2020. The ASUs did not have a material impact on our consolidated financial statements. ASU No. 2016-13 applies to all financial assets including loans, trade receivables and any other financial assets not excluded from the scope that have the contractual right to receive cash. The adoption of this ASU did not have any impact on our financial statements.
Equipment	Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no impairment losses recorded for the six June 30,	Equipment The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. In accordance with FASB ASC No. 360, Property, Plant and Equipment, There were no
Fair Value of Financial Instruments	Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at June 30, ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS June 30, 2021 December 31, 2020 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -	Fair Value of Financial Instruments We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” The three levels of the fair value hierarchy under ASC Topic 820-10 are described below: ● Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2020 and 2019. ● Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2020 December 31, 2019 Level 1 $ $ Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -
Revenue Recognition	Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017 and ending in September 2018, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the three and six June 30, 0 and $ 0 respectively in revenue. On January 25, 2021, the Company signed an amendment to a strategic partnership agreement with Kings Group for and exclusive sales agreement for up to $40 million. On April 8, 2021, the Company and Kings Group formed Spydasilk Enterprises Pte. Ltd., a Singapore company, to formalize this partnership.	Revenue Recognition The Company’s revenues have been generated primarily from a contract with the U.S. Government. The Company performed work under a cost-plus-fixed-fee contract. Under the base phase of that contract, the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017, to that original contract, the Company worked to develop new recombinant silks. Effective January 1, 2018, the Company adopted ASC No. 606 — Revenue from Contracts with Customers. Under ASC No. 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the years ended December 31, 2020 and 2019, the Company recognized $0 and $0 respectively in revenue from the Government contract. These revenues were generated for work performed in the development and production of the Company’s recombinant silks under the base and option period phases of our ongoing contract with the US Army. On July 24, 2017, the Company signed a contract option extension with the US Army to research and deliver recombinant spider silk fibers and threads. This contract option increased the total contract award by an additional $ 921,130 1,021,092
Concentration of Credit Risk	Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At June 30, 3,224,000 and $ 500,000 , respectively in excess of FDIC insurance limits. For the six June 30, 0 0	Concentration of Credit Risk The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2020 and December 31, 2019, the Company had approximately $ 500 0 For the years ended December 31, 2020 and 2019, the Company booked $ 0 0
Original Issue Discount	Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to interest expense in the consolidated statements of operations over the life of the debt.	Original Issue Discount For certain notes issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to interest expense in the consolidated statements of operations over the life of the debt.
Debt Issue Cost	Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument.	Debt Issue Cost Debt issuance cost paid to lenders, or third parties are recorded as debt discounts and amortized to interest expense in the consolidated statements of operations, over the life of the underlying debt instrument.
Beneficial Conversion Feature	Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt.
Organization		Organization Kraig Biocraft Laboratories, Inc. (the “Company”) was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries. On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary. On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd. On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.
Beneficial Conversion Feature		Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE	SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE June 30, 2021 December 31, 2020 Antidilutive Securities 114,490,727 76,460,919 Stock Warrants (Exercise price - $ 0.001 0.25 53,911,463 49,120,917 Stock Options (Exercise price - $ 0.1150 26,802,500 27,340,000 Convertible Debt 33,776,762 - Convertible Preferred Stock 2 2 Total 114,490,727 76,460,919	The computation of basic and diluted loss per share for December 31, 2020 and 2019 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2020 December 31, 2019 Stock Warrants (Exercise price - $ 0.001 0.16 49,120,917 57,995,917 Stock Options (Exercise price - $ 0.1150 27,340,000 - Convertible Preferred Stock 2 2 Total 76,460,919 57,995,919
SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS	SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS June 30, 2021 December 31, 2020 Level 1 $ - $ - Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -	SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS December 31, 2020 December 31, 2019 Level 1 $ $ Level 2 $ - $ - Level 3 $ - $ - Total $ - $ -
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES		The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2020 2019 Expected income tax (recovery) expense at the statutory rate of 21 $ (1,043,948 ) $ (610,845 ) Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes) 608,152 142,167 Change in valuation allowance 435,795 468,678 Provision for income taxes $ - $ -
SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES		The components of deferred income taxes are as follows: SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES Years Ended December, 2020 2019 Deferred tax liability: $ - $ - Deferred tax asset Net Operating Loss Carryforward 3,815,336 3,379,542 Valuation allowance (3,815,336 ) (3,379,542 ) Net deferred tax asset - - Net deferred tax liability $ - $ -

EQUIPMENT (Tables)

EQUIPMENT (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2021 December 31, 2020 Automobile $ 41,805 $ 41,805 Laboratory Equipment 101,656 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 85,389 85,389 Less: Accumulated Depreciation (155,189 ) (141,743 ) Total Property and Equipment, net $ 80,921 $ 89,247	At December 31, 2020 and December 31, 2019, property and equipment, net, is as follows: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, 2020 December 31, 2019 Automobile $ 41,805 $ 41,805 Laboratory Equipment 96,536 96,536 Office Equipment 7,260 7,260 Leasehold Improvements 85,389 85,389 Less: Accumulated Depreciation (141,743 ) (113,669 ) Total Property and Equipment, net $ 89,247 $ 117,321

RIGHT TO USE ASSETS AND LEASE_2

RIGHT TO USE ASSETS AND LEASE LIABILITITY (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Right To Use Assets And Lease Liabilitity
SCHEDULE OF RIGHT USE OF ASSETS	SCHEDULE OF RIGHT USE OF ASSETS June 30, 2021 Right to use assets, net 90,914 Right to use assets, net 241,800 Total $ 332,214	Right to use assets is summarized below: SCHEDULE OF RIGHT USE OF ASSETS December 31, Right to use assets, net – related party $ 44,849 Right to use assets, net 41,138 Right to use assets, net 279,038 Total $ 365,025
SCHEDULE OF LEASE LIABILITY	SCHEDULE OF LEASE LIABILITY June 30, 2021 Operating lease liability, net 90,223 Operating lease liability, net 254,462 Total 344,685 Less: short term portion (115,995 ) Long term position $ 228,690	Lease liability is summarized below: SCHEDULE OF LEASE LIABILITY December 31, Right to use liability, net – related party 47,418 Right to use liability, net 42,918 Right to use liability, net 289,385 Total 379,720 Less: short term portion $ (124,909 ) Long term position $ 254,811
SCHEDULE OF LEASE COST	SCHEDULE OF LEASE COST Operating lease expense $ 17,896 Operating lease expense $ 66,295 Operating lease expense – related party $ 3,683	Lease expense for the years ended December 31, 2020 was comprised of the following: SCHEDULE OF LEASE COST Operating lease expense $ 49,505 Operating lease expense $ 36,291 Operating lease expense – related party $ 13,092

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Convertible Notes
SCHEDULE OF FAIR VALUE WARRANTS	SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 % Stock Price $ 0.15 Exercise price $ 0.25 Expected term (in years) 5 Expected volatility 100.76 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.07 %	SCHEDULE OF FAIR VALUE WARRANTS Stock Price $ 0.14 Exercise price $ 0.16 Expected term (in years) 5 Expected volatility 60.64 % Annual rate of quarterly dividends 0 % Risk free interest rate 0.10 %
SUMMARY OF CONVERTIBLE DEBT	SUMMARY OF CONVERTIBLE DEBT The following represents a summary of the Company’s convertible debt at June 30, Convertible Note Payable Amounts In-Default Balance – December 31, 2020 50,505 - Proceeds – net 4,000,000 - Debt discount recorded (5,000,000 ) - Amortization of debt discount 2,084,468 - Balance – June 30, $ 1,134,973 $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2020 5,479 - Interest Expense June 30, 119,096 - Interest conversion into common shares (44,342 ) Balance – June 30, $ 80,233 $ -	The following represents a summary of the Company’s convertible debt at December 31, 2020: SUMMARY OF CONVERTIBLE DEBT Convertible Note Payable Amounts In-Default Balance – December 31, 2019 - Proceeds – net 950,000 - Original issue discount 50,000 - Debt discount recorded (1,000,000 ) - Amortization of debt discount 50,505 - Balance – December 31, 2020 $ 50,505 $ - Accrued Interest Payable Amounts In-Default Balance – December 31, 2019 - Interest Expense 2020 5,479 Balance – December 31, 2020 $ 5,479 $ -

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF OPTION ASSUMPTION	SCHEDULE OF OPTION ASSUMPTION On April 27, 2021, the Company extended the expiration date of the warrant issued on October 2, 2016 to October 1, 2026. During the six months ended June 30, 2021 the Company recorded an additional $ 217,715 as an expense for the warrant extension. Expected dividends 0 % Expected volatility 158.54 % Expected term 3 Risk free interest rate 1.37 % Expected forfeitures 0 % On February 2, 2021, the Company extended the expiration date of the warrant to May 29, 2026. During the six months ended June 30, 2021 the Company recorded an additional $ 85 as an expense for the warrant extension. Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % On January 1, 2016, the Company issued 3-year warrant to purchase 6,000,000 shares of common stock at $ 0.001 per share to a related party for services to be rendered. The warrants had a fair value of $ 142,526 , based upon the Black-Scholes option-pricing model on the date of grant and vested on February 20, 2017, and will be exercisable commencing on February 20, 2018, and for a period expiring on February 20, 2021. On February 2, 2021, the Company extended the expiration date of the warrant to May 29, 2026. During the six June 30, 85 as an expense for the warrant extension. Expected dividends 0 % Expected volatility 112 % Expected term 5 Risk free interest rate 0.18 % Expected forfeitures 0 % On January 25, 2021, the Company issued a 7-year option to purchase 2,500,000 shares of common stock at an exercise price of $ 0.134 per share to a related party for services rendered. The options had a fair value of $ 310,165 , based upon the Black-Scholes option-pricing model on the date of grant. Options vest 33.3% on the year one anniversary of the grant date, 33.3% will vest on the second anniversary, and 33.3% will vest on the third year anniversary as long as the employee remains with the Company. at the end of each successive year for three years. Options will be exercisable on January 25, 2021, and for a period of 7 years expiring on January 25, 2028. During the six June 30, 41,009 as an expense for options issued. Expected dividends 0 % Expected volatility 133.22 % Expected term 7 Risk free interest rate 1.46 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 10-year option to purchase 6,000,000 shares of common stock at an exercise price of $ 0.115 per share to a related party for services rendered. The options had a fair value of $ 626,047 , based upon the Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030. During the six June 30, $ 51,706 as an expense for options issued. Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % On February 19, 2020 the Company issued a 7-year option to purchase 1,340,000 shares of common stock at an exercise price of $ 0.115 per share to employees for services rendered. The options had a fair value of $ 133,063 , based upon the Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027. During the six June 30, 15,771 as an expense for options issued, net of $ 20,853 for the 800,000 options cancelled due to termination of employment. Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 3-year option to purchase 2,000,000 shares of common stock at an exercise price of $ 0.2299 per share to a related party for services rendered. The options had a fair value of $ 291,842 , based upon the Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. During the six June 30, 72,262 as an expense for options issued. Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 0.2299 18,240 Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026. 9,133 12,751 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % On August 8, 2019, the Company issued a 2-year options to purchase 125,000 0.2299 19,525 Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027. 6,520 9,103 Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 %	SCHEDULE OF OPTION ASSUMPTION Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.56 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 125.19 % Expected term 3 Risk free interest rate 1.50 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 125.19 % Expected term 6 Risk free interest rate 1.46 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 2 Risk free interest rate 1.62 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 105.73 % Expected term 3 Risk free interest rate 1.54 % Expected forfeitures 0 % Expected dividends 0 % Expected volatility 97.56 % Expected term 4 Risk free interest rate 2.65 % Expected forfeitures 0 %
SCHEDULE OF WARRANTS ACTIVITY	SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Weighted Balance, December 31, 2020 49,120,917 - 1.83 Granted 8,000,000 - - Exercised (2,959,456 ) - - Cancelled/Forfeited (250,000 ) - - Balance, June 30, 53,911,461 - 2.77 Intrinsic Value $ 2,895,566
SCHEDULE OF WARRANTS OUTSTANDING	SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 3.57 $ 1,311,000 $ 0.056 2,000,000 0.11 $ 128,000 $ 0.04 2,300,000 5.26 $ 184,000 $ 0.06 4,439,184 0.33 $ 532,702 $ 0.06 7,398,639 0.68 $ 443,918 $ 0.08 3,699,320 0.68 $ 147,973 $ 0.08 3,699,320 1.68 $ 147,973 $ 0.2299 8,250,000 3.72 $ - $ 0.16 3,125,000 4.45 $ - $ 0.25 8,000,000 4.73 $ - For the year ended December 31, 2020, the following warrants were outstanding: Exercise Price Warrants Exercisable Weighted Average Remaining Aggregate $ 0.001 11,000,000 1.19 $ 1,371,500 $ 0.056 2,000,000 0.60 $ 139,000 $ 0.04 2,300,000 0.65 $ 196,650 $ 0.06 7,398,639 0.18 $ 484,611 $ 0.06 7,398,639 1.18 $ 484,611 $ 0.08 3,699,320 1.18 $ 168,319 $ 0.08 3,699,320 2.18 $ 168,319 $ 0.2299 8,500,000 4.27 $ - $ 0.16 3,125,000 4.95 $ -	SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Exercise Price Weighted Balance, December 31, 2019 55,995,917 - 2.77 Granted 3,125,000 - - Exercised (10,000,000 ) - - Cancelled/Forfeited - - - Balance, December 31, 2020 49,120,917 - 1.83 Intrinsic Value $ 3,013,010
SCHEDULE OF OPTIONS OUTSTANDING	SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 26,802,500 19.62 For the year ended December 31, 2020, the following options were outstanding: Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 - 22,267,800 22.6
SCHEDULE OF OPTIONS OUTSTANDING		For the year ended December 31, 2020, the following options were outstanding: SCHEDULE OF OPTIONS OUTSTANDING Weighted Average Exercise Options Options Remaining Price Outstanding Exercisable Contractual Life $ 0.115 22,267,800 22.6
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF WARRANTS OUTSTANDING		For the year ended December 31, 2020, the following warrants were outstanding: SCHEDULE OF WARRANTS OUTSTANDING Exercise Price Warrants Weighted Average Aggregate $ 0.001 11,000,000 1.19 $ 1,371,500 $ 0.056 2,000,000 0.60 $ 139,000 $ 0.04 2,300,000 0.65 $ 196,650 $ 0.06 7,398,639 0.18 $ 484,611 $ 0.06 7,398,639 1.18 $ 484,611 $ 0.08 3,699,320 1.18 $ 168,319 $ 0.08 3,699,320 2.18 $ 168,319 $ 0.2299 8,500,000 4.27 $ - $ 0.16 3,125,000 4.95 $ - For the year ended December 31, 2019, the following warrants were outstanding: Exercise Price Warrants Weighted Average Aggregate $ 0.001 21,000,000 1.65 $ 4,069,800 $ 0.056 3,000,000 1.61 $ 387,600 $ 0.04 2,300,000 1.70 $ 445,740 $ 0.06 7,398,639 1.19 $ 1,433,856 $ 0.06 7,398,639 2.19 $ 1,433,856 $ 0.08 3,699,320 2.19 $ 716,928 $ 0.08 3,699,320 3.19 $ 719,928 $ 0.2299 8,500,000 5.39 $ 1,647,300

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	114,490,727	76,460,919	57,995,919
Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	53,911,463	49,120,917	57,995,917
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	26,802,500	27,340,000
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	33,776,762
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	2	2	2

SCHEDULE OF ANTIDILUTIVE SECU_2

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Warrant exercise price per share		$ 0.001	$ 0.16
Option exercise price	$ 0.1150	0.1150
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Warrant exercise price per share	0.001	0.001
Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Warrant exercise price per share	$ 0.25	$ 0.25

SCHEDULE OF FAIR VALUE OF FINAN

SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of assets and liabilities
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of assets and liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of assets and liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of assets and liabilities

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Jul. 24, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash equivalents					$ 0	$ 0
Impairment losses on equipment			$ 0	$ 0	0	0
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0	0	0
Cash excess of FDIC insurance limits	$ 3,224,000		3,224,000		500,000	0
Doubtful accounts			$ 0	$ 0	0	0
Valuation allowance increase decrease					$ 435,795	$ 610,845
Additional contract award							$ 921,130
Contract award							$ 1,021,092

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ 5,082,824		$ 6,631,299
Stockholders' deficiency	5,015,105	$ 6,313,603	6,573,564	$ 5,388,058	$ 6,876,767	$ 5,885,398	$ 4,459,223
Cash used in operating activities	$ 966,805	$ 697,909	$ 1,254,712	$ 1,087,878

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Less: Accumulated Depreciation	$ (155,189)	$ (141,743)	$ (113,669)
Total Property and Equipment, net	80,921	89,247	117,321
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	41,805	41,805	41,805
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	101,656	96,536	96,536
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	7,260	7,260	7,260
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 85,389	$ 85,389	$ 85,389

EQUIPMENT (Details Narrative)

EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 6,778	$ 5,740	$ 13,446	$ 13,118	$ 28,074	$ 30,781

SCHEDULE OF RIGHT USE OF ASSETS

SCHEDULE OF RIGHT USE OF ASSETS (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset, net	$ 332,214	$ 365,025	$ 473,242	$ 529,135
Right to Use Assets Net [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset, net	90,914	41,138
Right to Use Assets Net One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset, net	$ 241,800	279,038
Right to Use Assets Net - Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset, net		$ 44,849

SCHEDULE OF LEASE LIABILITY (De

SCHEDULE OF LEASE LIABILITY (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	$ 344,685	$ 379,720
Less: short term portion	(115,995)	(124,909)	$ (110,678)	$ (531,462)
Long term position	228,690	254,811	$ 369,281
Operating Lease Liability Net [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	90,223
Operating Lease Liability Net One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	$ 254,462
Right to Use Liability Net - Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total		47,418
Right to Use Liability Net [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total		42,918
Right to Use Liability Net One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total		$ 289,385

SCHEDULE OF LEASE COST (Details

SCHEDULE OF LEASE COST (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Operating Lease Expenses [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expenses	$ 17,896	$ 49,505
Operating Lease Expenses One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expenses	66,295	36,291
Operating Lease Expenses - Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expenses	$ 3,683	$ 13,092

RIGHT TO USE ASSETS AND LEASE_3

RIGHT TO USE ASSETS AND LEASE LIABILITITY (Details Narrative)	Sep. 05, 2019USD ($)ft²	May 09, 2019USD ($)ft²	Sep. 13, 2017USD ($)	Jan. 23, 2017USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Apr. 16, 2021USD ($)	Jan. 02, 2019USD ($)
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Rent payments									$ 2,508
Lessee, Operating Lease, Renewal Term				8 years
Rent payments				$ 960	$ 3,683	$ 6,263			2,508
Area of land | ft²	5,000
Annual rent, year one	$ 42,000		$ 39,200							$ 42,000
Annual rent, year two	$ 44,800		$ 42,000							$ 44,800
Right of use assets					332,214		$ 365,025	$ 473,242	365,025		$ 529,135
Lease liabilities					115,995		$ 124,909	110,678	$ 124,909		$ 531,462
Lease term description	two-year		two year
Lease percentage							8.00%		8.00%
Lease present value							$ 559,568		$ 559,568
Lease expenses							98,888
Related Party [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Rent payments							$ 13,092	$ 14,793
Socialist Republic of Vietnam [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Lessee, Operating Lease, Renewal Term		5 years
Area of land | ft²		4,560.57
Annual rent, year one		$ 45,150
Annual rent, year two		$ 45,150
Rent increase percentage		5.00%
Socialist Republic of Vietnam [Member] | Three through Five Years [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Rent increase percentage		5.00%
Adoption of NewGuidance [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Right of use assets					79,862
Lease liabilities					$ 79,862

ACCRUED INTEREST _ RELATED PA_2

ACCRUED INTEREST – RELATED PARTY (Details Narrative) - USD ($)	Dec. 01, 2020	Dec. 01, 2020	Nov. 17, 2020	Nov. 04, 2020	Oct. 19, 2020	Sep. 10, 2020	Aug. 12, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Mar. 09, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Mar. 01, 2019	Feb. 19, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Apr. 26, 2018	Mar. 31, 2018	Jan. 08, 2018	Dec. 01, 2017	Jun. 06, 2016	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from debt	$ 70,000	$ 70,000	$ 35,000	$ 30,000	$ 30,000	$ 100,000	$ 100,000	$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 20,000	$ 100,000	$ 20,000	$ 30,000	$ 30,000	$ 3,000	$ 20,000	$ 11,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 15,000	$ 100,000	$ 30,000	$ 50,000
Debt instrument, interest rate																																			3.00%
Loans payable amount																																	$ 1,657,000		$ 1,657,000	$ 642,000
In-kind contribution of interest																																	41,085	$ 21,972	50,763	22,337
Accrued interest																																	26,662
Accrued interest																																	$ 108,900	$ 14,161	$ 36,562	$ 15,581
Loan One [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from debt																					$ 17,000

NOTE PAYABLE (Details Narrative

NOTE PAYABLE (Details Narrative) - USD ($)	Mar. 05, 2021	Apr. 16, 2020	Mar. 01, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Short-term Debt [Line Items]
Debt instrument, interest rate								3.00%
Repayment of debt						$ 25,000	$ 30,000	$ 40,000	$ 20,000
Forgiven percentage	100.00%
Gain on debt extinguishment	$ 90,100					90,100
First Six Months [Member]
Short-term Debt [Line Items]
Repayment of debt						1,000		1,000
Seven and Eight Months [Member]
Short-term Debt [Line Items]
Repayment of debt						2,000		2,000
Nine Through Twenty Three Months [Member]
Short-term Debt [Line Items]
Repayment of debt						5,000		5,000
24th Month [Member]
Short-term Debt [Line Items]
Notes payable				$ 180,224		$ 180,224		$ 180,224
Unsecured Promissory Note [Member] | Notre Dame [Member]
Short-term Debt [Line Items]
Notes payable			$ 265,244
Debt instrument, interest rate			10.00%
Debt instrument term, description			twenty four months
Huntington National Bank [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate		1.00%
Loan		$ 90,100
Debt instrument maturity date		Apr. 16, 2022

SCHEDULE OF FAIR VALUE WARRANTS

SCHEDULE OF FAIR VALUE WARRANTS (Details)	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term	5 years	5 years
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.14	0.14
Measurement Input, Share Price [Member] | Additional Issuance of Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.15
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.16	0.16
Measurement Input, Exercise Price [Member] | Additional Issuance of Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.25
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term	5 years	5 years
Measurement Input, Expected Term [Member] | Additional Issuance of Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term	5 years
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	60.64	0.6064
Measurement Input, Price Volatility [Member] | Additional Issuance of Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	100.76
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0	0
Measurement Input, Expected Dividend Rate [Member] | Additional Issuance of Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.10	0.0010
Measurement Input, Risk Free Interest Rate [Member] | Additional Issuance of Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.07

SUMMARY OF CONVERTIBLE DEBT (De

SUMMARY OF CONVERTIBLE DEBT (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Transfer of Financial Assets Accounted for as Sales [Line Items]
Balance	$ 50,505
Proceeds - net	3,670,000		950,000
Balance	1,134,973		50,505
Balance - Accrued Interest Payable	5,479
Balance, In-Default
Interest Expense	119,096		5,479
Interest conversion into common shares	(44,342)
Balance - Accrued Interest Payable	80,233		5,479
Balance, In-Default
Balance - Accrued Interest Payable	5,479
Balance - Accrued Interest Payable			5,479
Convertible Notes Payable [Member]
Transfer of Financial Assets Accounted for as Sales [Line Items]
Balance	50,505
Balance, In-Default
Proceeds - net	4,000,000		950,000
Debt discount recorded	(5,000,000)		(1,000,000)
Amortization of debt discount	2,084,468		50,505
Balance	1,134,973		50,505
Balance, In-Default
Original issue discount			$ 50,000

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative) - USD ($)	Jun. 23, 2021	Jun. 07, 2021	Apr. 30, 2021	Apr. 26, 2021	Apr. 23, 2021	Apr. 23, 2021	Apr. 06, 2021	Mar. 25, 2021	Dec. 11, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt Instrument, interest rate												3.00%
Debt instrument, discount										$ 2,865,027		$ 949,495	$ 0
Proceeds from convertible note										$ 3,670,000		$ 950,000
Number of warrants issued										8,000,000		3,125,000
Warrants term										5 years		5 years
Fair value of warrants										$ 3,359,716		$ 2,599,066
Debt Instrument, Increase, Accrued Interest										41,085	$ 26,662
Common Stock [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	2,422,195	2,431,506	2,058,686	2,063,391		836,574
Debt Conversion, Converted Instrument, Amount	$ 200,000	$ 200,000	$ 250,000	$ 250,000		$ 100,000
Debt Instrument, Increase, Accrued Interest	$ 10,247	25,644	3,630	$ 3,178		$ 1,644
Fair Value of Issued Shares.		$ 297,373	$ 338,654
Unsecured, Convertible Note [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Convertible note value								$ 4,000,000	$ 1,000,000
Debt instrument, maturity date									Jan. 11, 2022
Debt Instrument, interest rate									10.00%
Debt Instrument, discount rate									5.00%
Debt instrument, discount									$ 50,000	3,000,000		1,000,000
Proceeds from convertible note									$ 950,000
Debt instrument, description									The note contains a discount to market feature, whereby, the lender can purchase stock at 90% of the lowest trading price for a period of ten (10) days preceding the conversion date
Debt issuance costs										$ 330,000		$ 86,000
Debt instrument term, description									thirteen-month
Unsecured, Convertible Note [Member] | First Convertible Debenture [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Convertible note value								$ 500,000
Debt instrument, maturity date								Mar. 25, 2022
Debt Instrument, interest rate								10.00%
Debt instrument term, description								one year
Unsecured, Convertible Note [Member] | Secound Convertible Debenture [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Convertible note value							$ 500,000
Unsecured, Convertible Note [Member] | Third Convertible Debenture [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Convertible note value					$ 3,000,000

SCHEDULE OF OPTION ASSUMPTION (

SCHEDULE OF OPTION ASSUMPTION (Details)	Apr. 27, 2021	Feb. 02, 2021	Jan. 25, 2021	Feb. 19, 2020	Feb. 19, 2020	Aug. 08, 2019	Aug. 08, 2019	Aug. 08, 2019	Mar. 20, 2018	Jan. 02, 2016
Common Stock Warrants and Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends	0.00%	0.00%	0.00%	0.00%	0.00%					0.00%
Expected volatility	158.54%	112.00%	133.22%	125.19%	125.19%					112.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years	5 years	7 years	3 years	3 years					5 years
Risk free interest rate	1.37%	0.18%	1.46%	1.56%	1.50%					0.18%
Expected forfeitures	0.00%	0.00%	0.00%	0.00%	0.00%					0.00%
Common Stock Warrants and Options One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends				0.00%	0.00%
Expected volatility				125.19%	125.19%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				3 years	6 years
Risk free interest rate				1.50%	1.46%
Expected forfeitures				0.00%	0.00%
Common Stock Warrants and Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%		0.00%
Expected volatility						105.73%		105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years		3 years
Risk free interest rate						1.62%		1.54%
Expected forfeitures						0.00%		0.00%
Common Stock Warrants and Options One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%	0.00%
Expected volatility						105.73%	105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years	3 years
Risk free interest rate						1.62%	1.54%
Expected forfeitures						0.00%	0.00%
Common Stock Warrants and Options Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						3 years
Risk free interest rate						1.54%
Expected forfeitures						0.00%
Common Stock Warrants and Options Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends					0.00%
Expected volatility					125.19%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term					6 years
Risk free interest rate					1.46%
Expected forfeitures					0.00%
Common Stock Warrants and Options Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years
Risk free interest rate						1.62%
Expected forfeitures						0.00%
Common Stock Warrants and Options Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years
Risk free interest rate						1.62%
Expected forfeitures						0.00%
Common Stock Warrants and Options Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years
Risk free interest rate						1.62%
Expected forfeitures						0.00%
Common Stock Warrants and Options Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years
Risk free interest rate						1.62%
Expected forfeitures						0.00%
Common Stock Warrants and Options Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						3 years
Risk free interest rate						1.54%
Expected forfeitures						0.00%
Common Stock Warrants and Options Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends						0.00%
Expected volatility						105.73%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						3 years
Risk free interest rate						1.54%
Expected forfeitures						0.00%
Common Stock Warrants and Options Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividends									0.00%
Expected volatility									97.56%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term									4 years
Risk free interest rate									2.65%
Expected forfeitures									0.00%

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Warrants, Beginning balance	49,120,917	55,995,917
Weighted Average Exercise Price, Beginning balance
Weighted Average Remaining Contractual Life (In Years), Beginning balance	1 year 9 months 29 days	2 years 9 months 7 days
Number of Warrants, Beginning balance	8,000,000	3,125,000
Weighted Average Exercise Price, Beginning balance
Number of Warrants, Beginning balance	(2,959,456)	(10,000,000)
Weighted Average Exercise Price, Beginning balance
Number of Warrants, Cancelled/Forfeited	(250,000)
Weighted Average Exercise Price, Beginning balance
Number of Warrants, Beginning balance	53,911,461	49,120,917
Weighted Average Exercise Price, Intrinsic Value
Weighted Average Remaining Contractual Life (In Years), Ending balance	2 years 9 months 7 days	1 year 9 months 29 days
Number of Warrants, Intrinsic Value	$ 2,895,566	$ 3,013,010
Number of Warrants, Beginning balance	250,000
Weighted Average Exercise Price, Beginning balance
Number of Warrants, Beginning balance	$ 2,895,566	$ 3,013,010

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 30, 2020	Dec. 31, 2019	Mar. 02, 2021	Mar. 09, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding		$ 0.001		$ 0.16
Weighted Average Remaining Contractual Life	1 year 9 months 29 days	2 years 9 months 7 days
Aggregate Intrinsic Value	$ 2,895,566	$ 3,013,010
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.001	$ 0.001		$ 0.001	$ 0.06	$ 0.06
Warrants Exercisable	11,000,000	11,000,000		21,000,000
Weighted Average Remaining Contractual Life	3 years 6 months 25 days	1 year 2 months 8 days	1 year 2 months 8 days	1 year 7 months 24 days
Aggregate Intrinsic Value	$ 1,311,000	$ 1,371,500		$ 4,069,800
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.056	$ 0.056		$ 0.056	0.06	0.06
Warrants Exercisable	2,000,000	2,000,000		3,000,000
Weighted Average Remaining Contractual Life	1 month 9 days	7 months 6 days		1 year 7 months 9 days
Aggregate Intrinsic Value	$ 128,000	$ 139,000		$ 387,600
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.04	$ 0.04		$ 0.04	0.06	0.08
Warrants Exercisable	2,300,000	2,300,000		2,300,000
Weighted Average Remaining Contractual Life	5 years 3 months 3 days	7 months 24 days		1 year 8 months 12 days
Aggregate Intrinsic Value	$ 184,000	$ 196,650		$ 445,740
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.06	$ 0.06		$ 0.06	0.06	$ 0.08
Warrants Exercisable	4,439,184	7,398,639		7,398,639
Weighted Average Remaining Contractual Life	3 months 29 days	2 months 4 days		1 year 2 months 8 days
Aggregate Intrinsic Value	$ 532,702	$ 484,611		$ 1,433,856
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.06	$ 0.06		$ 0.06	$ 0.06
Warrants Exercisable	7,398,639	7,398,639		7,398,639
Weighted Average Remaining Contractual Life	8 months 4 days	1 year 2 months 4 days		2 years 2 months 8 days
Aggregate Intrinsic Value	$ 443,918	$ 484,611		$ 1,433,856
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.08	$ 0.08		$ 0.08
Warrants Exercisable	3,699,320	3,699,320		3,699,320
Weighted Average Remaining Contractual Life	8 months 4 days	1 year 2 months 4 days		2 years 2 months 8 days
Aggregate Intrinsic Value	$ 147,973	$ 168,319		$ 716,928
Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.08	$ 0.08		$ 0.08
Warrants Exercisable	3,699,320	3,699,320		3,699,320
Weighted Average Remaining Contractual Life	1 year 8 months 4 days	2 years 2 months 4 days		3 years 2 months 8 days
Aggregate Intrinsic Value	$ 147,973	$ 168,319		$ 719,928
Warrant Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.2299	$ 0.2299		$ 0.2299
Warrants Exercisable	8,250,000	8,500,000		8,500,000
Weighted Average Remaining Contractual Life	3 years 8 months 19 days	4 years 3 months 7 days		5 years 4 months 20 days
Aggregate Intrinsic Value				$ 1,647,300
Warrant Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.16	$ 0.16
Warrants Exercisable	3,125,000	3,125,000
Weighted Average Remaining Contractual Life	4 years 5 months 12 days	4 years 11 months 12 days
Aggregate Intrinsic Value
Warrant Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price Warrants Outstanding	$ 0.25
Warrants Exercisable	8,000,000
Weighted Average Remaining Contractual Life	4 years 8 months 23 days
Aggregate Intrinsic Value

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Exercise Price	$ 0.115	$ 0.115
Options Outstanding
Options Exercisable	26,802,500	22,267,800
Weighted Average Remaining Contractual Life	19 years 7 months 13 days	22 years 7 months 6 days

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)

Jun. 23, 2021

Jun. 07, 2021

Apr. 30, 2021

Apr. 27, 2021

Apr. 26, 2021

Apr. 23, 2021

Mar. 05, 2021

Mar. 02, 2021

Feb. 24, 2021

Feb. 02, 2021

Jan. 25, 2021

Jul. 30, 2020

Feb. 19, 2020

Sep. 26, 2019

Aug. 14, 2019

Aug. 08, 2019

Apr. 05, 2019

Mar. 20, 2019

Mar. 09, 2019

Mar. 20, 2018

Jan. 02, 2016

Feb. 16, 2009

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Aug. 08, 2020

Dec. 31, 2019

May 04, 2021

Mar. 08, 2019

Dec. 17, 2013

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

766,667

7,967,871

4,052,652

Share price

$ 0.0695

Proceeds from issuance of common stock

$ 1,000,000

Warrants to purchase up share

1,000,000

8,000,000

Warrant exercise price per share

$ 0.001

$ 0.16

Stock issued during period, value

$ 281,659

$ 1,000,000

Issuance of common stock in connection with cashless exercise

786,280

70,786

9,941,623

1,479,728

3,816,522

10,000,000

9,000,000

Fair value of adjustments of warrants

$ 3,359,716

$ 2,599,066

Cancellation of warrants

(42,707)

Debt Instrument, Increase, Accrued Interest

41,085

$ 26,662

Gain (Loss) on Extinguishment of Debt

$ 90,100

$ 90,100

Warrants term

5 years

5 years

5 years

Number of warrants cancelled

250,000

Preferred stock, shares authorized

Unlimited

Unlimited

Unlimited

Unlimited

Preferred stock, no par value

$ 0

$ 0

$ 0

$ 0

$ 0

Contribution of capital

$ 17,495

$ 17,495

Common Class A [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock, shares authorized

Unlimited

Unlimited

Unlimited

Unlimited

Common stock, no par value

$ 0

0

$ 0

$ 0

$ 0

Common Class B [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock, shares authorized

Unlimited

Unlimited

Unlimited

Unlimited

Common stock, no par value

$ 0

0

$ 0

$ 0

$ 0

Series A Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Preferred stock, no par value

0

0

0

0

$ 0

Preferred stock, shares authorized

2

University of Notre Dame [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued during period, value

38,500

Accounts payable

$ 243,159

6 Cent Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase up share

14,797,278

Warrant exercise price per share

$ 0.06

8 Cent Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase up share

7,398,639

Warrant exercise price per share

$ 0.08

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase up share

1,479,728

1,479,728

Warrant exercise price per share

$ 0.06

$ 0.06

0.001

0.001

0.001

0.001

Warrant expiration date

Mar. 8, 2021

Mar. 8, 2021

Stock issued during period, value

$ 88,784

Issuance of common stock in connection with cashless exercise

2,000,000

200,000

10,000,000

Warrant One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase up share

1,479,728

Warrant exercise price per share

$ 0.06

$ 0.06

0.056

0.056

0.056

0.056

Warrant expiration date

May 8, 2021

Mar. 8, 2022

Warrant Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase up share

1,479,728

Warrant exercise price per share

$ 0.06

$ 0.08

0.04

0.04

0.04

0.04

Warrant expiration date

Jul. 8, 2021

Mar. 8, 2022

Warrant Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase up share

1,479,728

Warrant exercise price per share

$ 0.06

$ 0.08

0.06

0.06

0.06

0.06

Warrant expiration date

Sep. 8, 2021

Mar. 8, 2023

Warrant Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase up share

1,479,727

Warrant exercise price per share

$ 0.06

$ 0.06

$ 0.06

$ 0.06

$ 0.06

Warrant expiration date

Nov. 8, 2021

Common Stock Warrants and Options [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

2,500,000

20,000,000

2,000,000

Share price

$ 0.134

$ 0.115

$ 0.2299

$ 0.001

Warrants to purchase up share

600,000

6,000,000

Warrant exercise price per share

$ 0.001

Share based compensation, expense

$ 217,715

$ 85

$ 85

Fair value of adjustments of warrants

$ 19,915

$ 142,526

[custom:FairValueOfOptions]

$ 310,165

Common stock warrants and options, description

Options vest 33.3% on the year one anniversary of the grant date, 33.3% will vest on the second anniversary, and 33.3% will vest on the third year anniversary as long as the employee remains with the Company. at the end of each successive year for three years.

Option term

20 years

2 years

Fair value of options

$ 2,198,411

$ 267,574

Common stock warrants and options, description

Options will be exercisable on February 19, 2025, and for a period of 15 years expiring on February 19, 2040

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2024

Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022

Share based compensation

$ 2,198,411

$ 267,574

Warrants term

4 years

Number of warrants cancelled

600,000

Warrants cancelled amount

$ 6,000

Warrants and Options [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation, expense

41,009

Common Stock Warrants and Options One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

6,000,000

Share price

$ 0.115

Share based compensation, expense

51,706

[custom:FairValueOfOptions]

$ 626,047

Option term

10 years

Fair value of options

$ 626,047

Common stock warrants and options, description

Black-Scholes option-pricing model on the date of grant and 2,000,000 options are fully vested on the date granted and 1,000,000 options vest at the end of each successive year for four years. Options will be exercisable on February 19, 2021, and for a period of 10 years expiring on February 19, 2030

Share based compensation

272,673

Common Stock Warrants and Options Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

1,340,000

Share price

$ 0.115

Share based compensation, expense

15,771

[custom:FairValueOfOptions]

$ 133,063

Common stock warrants and options, description

Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027.

[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue]

$ 20,853

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

800,000

Option term

7 years

Fair value of options

$ 133,063

Common stock warrants and options, description

Black-Scholes option-pricing model on the date of grant and 268,000 options are fully vested on the date granted and the remaining option vest equally over the remaining 4 years at the end of each successive year. Options will be exercisable on February 19, 2021, and for a period of 6 years expiring on February 19, 2027

Share based compensation

40,935

Common Stock Warrants and Options Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

2,000,000

Share price

$ 0.2299

Share based compensation, expense

$ 72,262

[custom:FairValueOfOptions]

$ 291,842

Common stock warrants and options, description

Black-Scholes option-pricing model on the date of grant and is fully vested on August 8, 2021. Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026.

Option term

3 years

Fair value of options

$ 291,842

Common stock warrants and options, description

Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026

Share based compensation

146,121

Common Stock Warrants and Options Seven [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

125,000

Share price

$ 0.2299

Share based compensation, expense

9,133

12,751

Fair value of adjustments of warrants

$ 18,240

Common stock warrants and options, description

Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026.

Option term

2 years

Fair value of options

$ 18,240

Common stock warrants and options, description

Options will be exercisable on August 8, 2023, and for a period of 3 years expiring on August 8, 2026

Share based compensation

9,133

Common Stock Warrants and Options Eight [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

125,000

Share price

$ 0.2299

Share based compensation, expense

$ 6,520

Fair value of adjustments of warrants

$ 19,525

Common stock warrants and options, description

Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027.

Cancellation of warrants

$ 9,103

Option term

2 years

Fair value of options

$ 19,525

Common stock warrants and options, description

Options will be exercisable on August 8, 2024, and for a period of 3 years expiring on August 8, 2027

Share based compensation

6,520

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued

2,422,195

2,431,506

2,058,686

2,063,391

836,574

Debt Conversion, Converted Instrument, Amount

$ 200,000

$ 200,000

$ 250,000

$ 250,000

$ 100,000

Debt Instrument, Increase, Accrued Interest

$ 10,247

25,644

3,630

$ 3,178

$ 1,644

Fair Value of Issued Shares.

297,373

$ 338,654

Gain (Loss) on Extinguishment of Debt

$ 71,729

Common Stock and Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

14,797,278

Common Stock Warrants and Options One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

2,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 267,574

Common stock warrants and options, description

Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025

Share based compensation

161,568

Common Stock Warrants and Options Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

1,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 118,874

Common stock warrants and options, description

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023

Share based compensation

118,874

Common Stock Warrants and Options Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

1,000,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 118,874

Common stock warrants and options, description

Options will be exercisable on August 8, 2021, and for a period of 3 years expiring on August 8, 2024

Share based compensation

118,874

Common Stock Warrants and Options Five [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 14,859

Common stock warrants and options, description

Options will be exercisable on August 8, 2020, and for a period of 3 years expiring on August 8, 2023

Share based compensation

14,859

Common Stock Warrants and Options Six [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

125,000

Share price

$ 0.2299

Option term

2 years

Fair value of options

$ 16,723

Common stock warrants and options, description

Options will be exercisable on August 8, 2022, and for a period of 3 years expiring on August 8, 2025

Share based compensation

10,098

Common Stock Warrant and Options [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants expenses

$ 19,915

Chief Financial Officer [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Contribution of capital

$ 17,495

Purchase Agreement [Member] | Investor [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

14,797,278

Share price

$ 0.06758

Proceeds from issuance of common stock

$ 1,000,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Jul. 29, 2021USD ($)shares	Jul. 20, 2021USD ($)shares	Jul. 06, 2021USD ($)shares	Oct. 21, 2019USD ($)	Sep. 26, 2019shares	Sep. 05, 2019USD ($)ft²	Aug. 15, 2019USD ($)	Aug. 15, 2019USD ($)	Aug. 14, 2019shares	Aug. 08, 2019$ / sharesshares	Jul. 03, 2019$ / sharesshares	Jul. 03, 2019USD ($)$ / sharesshares	May 09, 2019USD ($)ft²	Apr. 26, 2019USD ($)	Apr. 05, 2019shares	Mar. 20, 2019USD ($)shares	Jan. 31, 2019USD ($)shares	Mar. 20, 2018USD ($)$ / sharesshares	Feb. 20, 2018USD ($)shares	Jan. 09, 2018	Sep. 13, 2017USD ($)	Sep. 13, 2017USD ($)	Jan. 23, 2017USD ($)	Jan. 14, 2016$ / sharesshares	Jan. 14, 2016USD ($)$ / sharesshares	May 28, 2015$ / sharesshares	Jan. 20, 2015$ / sharesshares	Jan. 20, 2015USD ($)$ / sharesshares	Oct. 28, 2011USD ($)shares	Nov. 10, 2010USD ($)	Dec. 26, 2006USD ($)shares	May 08, 2006USD ($)	Jan. 31, 2007USD ($)	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2020USD ($)$ / shares	Jul. 01, 2021ft²	Apr. 16, 2021USD ($)
Loss Contingencies [Line Items]
Annual salary																																		$ 171,694	$ 54,853	$ 331,592	$ 199,415		$ 516,332	$ 627,197
Accrued salary balance																																		2,924,436	3,018	2,924,436	3,018		$ 2,804,725							$ 2,804,725
Warrant exercise price per share | $ / shares																																							$ 0.001	$ 0.16						$ 0.001
Payroll payable																																		$ 29,943		$ 29,943
Number of shares issued | shares					766,667				7,967,871							4,052,652
[custom:LicenseTerminationFee-0]																													$ 5,000
Warrants term																																		5 years		5 years			5 years							5 years
Payment for debt																																				$ 25,000	30,000		$ 40,000	$ 20,000
Stock issued during period, value																$ 281,659																								1,000,000
Interest and Debt Expense																																				490
Interest Payable, Current																																		$ 80,233		$ 80,233			5,479							$ 5,479
Payments for rent																																														2,508
Operating lease, description																																				On April 16, 2021, the Company signed a two year amendment to this lease. Commencing on July 1, 2021 and ending on September 30, 2022, the Company will pay an annualized rent of $42,000. From October 1, 2022 through September 30, 2023, the Company will pay an annual rent of $44,800.
Area of land | ft²						5,000
Annual rent, year two						$ 44,800															$ 42,000	$ 42,000																										$ 44,800
Annual rent, year one						$ 42,000															39,200	39,200																										$ 42,000
Payments for rent																							$ 960													$ 3,683	6,263									2,508
Interest expense and related accrued interest payable																																		$ 108,900	14,161	108,900	14,161		36,562	15,581						$ 36,562
Fair value of warrants																																				$ 3,359,716			$ 2,599,066
Socialist Republic of Vietnam [Member]
Loss Contingencies [Line Items]
Area of land | ft²													4,560.57
Annual rent, year two													$ 45,150
Annual rent, year one													$ 45,150
Rent increase percentage													5.00%
Socialist Republic of Vietnam [Member] | Three through Five Years [Member]
Loss Contingencies [Line Items]
Rent increase percentage													5.00%
Maximum [Member]
Loss Contingencies [Line Items]
Warrant exercise price per share | $ / shares																																		$ 0.25		$ 0.25			$ 0.25							$ 0.25
Minimum [Member]
Loss Contingencies [Line Items]
Warrant exercise price per share | $ / shares																																		$ 0.001		$ 0.001			$ 0.001							$ 0.001
Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of shares issued | shares	3,101,546	1,664,823	2,343,919
Lessee, Operating Lease, Term of Contract																																															5 years
Area of land | ft²																																															36,000
Interest expense and related accrued interest payable	$ 11,836	$ 60,822	$ 7,671
Mr. Jonathan R. Rice [Member]
Loss Contingencies [Line Items]
Payroll payable																																		$ 29,943		$ 29,943			$ 103,730	64,352						$ 103,730
Mr.Rice [Member]
Loss Contingencies [Line Items]
Payroll payable																																								64,351
Mr. Kenneth Le [Member]
Loss Contingencies [Line Items]
Accrued salary balance																																		3,018		3,018			888							888
Board of Directors Chairman [Member]
Loss Contingencies [Line Items]
Accrued salary balance																																			$ 3,018		$ 3,018		888	1,153						888
Employment Agreement [Member]
Loss Contingencies [Line Items]
Extended expiration date description																				the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 10, 2025 for Mr. Rice.
Employment Agreement [Member] | Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Agreement Term Description																														five year
Annual salary																														$ 210,000								$ 398,643	$ 376,078	$ 354,791		$ 315,764	$ 297,889	$ 297,889	$ 281,027
Annual salary rate, increase																														6.00%
Agreement term																														5 years									5 years	5 years		5 years	5 years	5 years
Accrued salary balance																																							$ 2,804,725	$ 2,535,203						2,804,725
Employment Agreement [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Annual salary																																						$ 398,643
Employment Agreement [Member] | Employee [Member]
Loss Contingencies [Line Items]
Employee bonus rate																																													20.00%
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]
Loss Contingencies [Line Items]
Annual salary				$ 20,000			$ 20,000	$ 20,000						$ 20,000
Agreement term																									1 year			1 year
Annual cash compensation																									$ 140,000			$ 120,000
Educational expenses																												$ 11,000
Warrant to purchase common stock shares | shares										6,000,000														6,000,000	6,000,000
Warrant exercise price per share | $ / shares										$ 0.2299														$ 0.001	$ 0.001
Warrants term, description																								three-year	three
Warrants maturity date																								May 20, 2026	May 20, 2026
Warrants issued value																																													$ 121,448
Extended expiration date description																				the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019.
One-time bonus														$ 20,000
Working capital				$ 6,000,000			$ 6,000,000	$ 6,000,000
Ownership percentage				50.00%			50.00%	50.00%
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Warrants term, description										five
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Warrants term, description										three
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | January 2015 Warrant [Member]
Loss Contingencies [Line Items]
Warrant to purchase common stock shares | shares																											2,000,000	2,000,000
Warrant exercise price per share | $ / shares																											$ 0.001	$ 0.001
Warrants term, description																											three
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member] | May 2015 Warrant [Member]
Loss Contingencies [Line Items]
Warrant to purchase common stock shares | shares																										3,000,000
Warrant exercise price per share | $ / shares																										$ 0.001
Warrants term, description																										three-year
Warrants maturity date																										May 28, 2022
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Loss Contingencies [Line Items]
Agreement term												1 year
Accrued salary balance																																							888	1,154						888
Annual cash compensation												$ 60,000
Warrant to purchase common stock shares | shares											2,000,000	2,000,000
Warrant exercise price per share | $ / shares											$ 0.2299	$ 0.2299
Warrants term, description											three	three-year
Salary Increment [Member] | Mr.Rice [Member]
Loss Contingencies [Line Items]
Annual salary				$ 20,000
Employment Agreement [Member] | Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Annual salary																																								$ 334,708
Agreement term																																								5 years
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Loss Contingencies [Line Items]
Warrants term, description												three-year
License Agreement [Member]
Loss Contingencies [Line Items]
Agreement term																													20 years
License fee																																$ 10,000
License maintenance fee																																$ 10,000
Annual research fee																																	$ 13,700
Number of shares issued | shares																													2,200,000
Royalty percentage																													2.00%
Payment for debt																																							40,000
Interest Payable, Current																																		9,483		9,483
Payments for rent																																				960
Termination agreement description																													The Company can terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years.
License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Annual research fee																																	$ 10,000
License Agreement [Member] | Common Class A [Member]
Loss Contingencies [Line Items]
Number of shares issued | shares																	4,025,652
Payment for debt																	$ 265,244
Stock issued during period, value																	$ 281,659
Consulting Agreement [Member] | Consultant [Member]
Loss Contingencies [Line Items]
Annual cash compensation																			$ 6,000
Warrant to purchase common stock shares | shares																		600,000	600,000
Warrant exercise price per share | $ / shares																		$ 0.001
Warrants term																		4 years											4 years
Fair value of warrants																		$ 19,915
Warrants exercisable description																		Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022
Warrants exercisable date																		Mar. 20, 2019
Warrants expenses																																									$ 19,915
Cancelled warrant issued | shares															600,000
Consulting Agreement [Member] | Consultant [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Warrant to purchase common stock shares | shares																			3,000,000
Royalty and Research Agreements [Member]
Loss Contingencies [Line Items]
Interest expense and related accrued interest payable																																							8,503	$ 2,623						8,503
Royalty and Research Agreements [Member] | Mr. Thompson [Member]
Loss Contingencies [Line Items]
Payment for debt																															$ 120,000
Outstanding balance																																							65,292	65,292						65,292
Debt instrument maturity date																															Dec. 26, 2007
Interest expense and related accrued interest payable																																							1,960							1,960
Intellectual Property Transfer Agreement [Member] | Mr. Thompson [Member]
Loss Contingencies [Line Items]
Number of shares issued | shares																															200,000
Stock issued during period, value																															$ 120,000
Outstanding balance																																		65,292		65,292			65,292							65,292
Debt instrument maturity date																															Dec. 26, 2007
Interest expense and related accrued interest payable																																		$ 9,483		9,483			8,503							$ 8,503
Operating Lease Agreements [Member]
Loss Contingencies [Line Items]
Payments for rent																																				$ 2,508
Operating lease, description						the Company signed a new two-year lease for this 5,000 square foot property in Lansing, MI that commenced on October 1, 2019 and ends on September 30, 2021, for its research and development headquarters.
Lessee, Operating Lease, Term of Contract																							8 years
Area of land | ft²						5,000
Annual rent, year two						$ 44,800
Annual rent, year one						42,000															$ 39,200	39,200
Payments for rent						$ 44,800																																	2,508
Lease term description						two-year															two-year
Operating leases, rent expense																																							9,819	$ 11,913
Operating Lease Agreements [Member] | Office and Manufacturing Space [Member]
Loss Contingencies [Line Items]
Annual rent, year two																					$ 42,000	42,000
Payments for rent																						$ 42,000
Operating Lease Agreements [Member] | Socialist Republic of Vietnam [Member]
Loss Contingencies [Line Items]
Operating lease, description													the Company signed a
Lessee, Operating Lease, Term of Contract													5 years
Area of land | ft²													4,560.57
Annual rent, year two													$ 45,150
Annual rent, year one													$ 45,150
Operating lease, description													the Company signed a
Operating Lease Agreements [Member] | Socialist Republic of Vietnam [Member] | Three through Five Years [Member]
Loss Contingencies [Line Items]
Rent increase percentage													5.00%
Operating Lease Agreements [Member] | President [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract																							8 years
Payments for rent																							$ 960																$ 960

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 01, 2020	Nov. 17, 2020	Nov. 04, 2020	Oct. 19, 2020	Sep. 10, 2020	Aug. 12, 2020	Jul. 16, 2020	Jun. 03, 2020	Apr. 08, 2020	Mar. 09, 2020	Feb. 19, 2020	Jan. 24, 2020	Dec. 18, 2019	Nov. 20, 2019	Oct. 21, 2019	Sep. 26, 2019	Sep. 05, 2019	Aug. 15, 2019	Aug. 15, 2019	Aug. 14, 2019	Jul. 03, 2019	Jul. 03, 2019	Apr. 26, 2019	Mar. 20, 2019	Mar. 02, 2019	Mar. 01, 2019	Feb. 15, 2019	Feb. 01, 2019	Jan. 17, 2019	Jan. 05, 2019	Jan. 04, 2019	Jan. 04, 2019	Dec. 21, 2018	Oct. 12, 2018	Oct. 02, 2018	Oct. 01, 2018	Jul. 05, 2018	Jun. 29, 2018	Jun. 21, 2018	Jun. 05, 2018	Apr. 26, 2018	Mar. 31, 2018	Mar. 31, 2018	Jan. 09, 2018	Jan. 08, 2018	Jan. 08, 2018	Dec. 02, 2017	Jan. 23, 2017	Jun. 06, 2016	Jun. 06, 2016	Jan. 14, 2016	Jan. 14, 2016	Jan. 20, 2015	Nov. 10, 2010	Dec. 26, 2006	Dec. 26, 2006	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Aug. 14, 2020	Dec. 31, 2020	Aug. 08, 2019	Dec. 26, 2007
Related Party Transaction [Line Items]
Number of shares issued																766,667				7,967,871				4,052,652
Stock issued during period, value																								$ 281,659																																							$ 1,000,000
Debt Instrument, interest rate																																																														3.00%							3.00%
Interest expense and related accrued interest payable																																																									$ 108,900	$ 14,161	$ 108,900	$ 14,161		$ 36,562	15,581						$ 36,562
Annual salary																																																									171,694	54,853	331,592	199,415		516,332	$ 627,197
Accrued salary balance																																																									2,924,436	3,018	2,924,436	3,018		$ 2,804,725							$ 2,804,725
Warrant exercise price per share																																																														$ 0.001	$ 0.16						$ 0.001
Payroll payable																																																									29,943		29,943
Debt Instrument, Increase, Accrued Interest																																																											41,085	26,662
In-kind contribution of interest																																																											41,085	21,972		$ 50,763	$ 22,337
Payments for rent																																																$ 960											3,683	6,263									$ 2,508
Operating leases, rent expense																																																											3,683	6,263
Related Party [Member]
Related Party Transaction [Line Items]
Interest expense and related accrued interest payable																																																									1,732,191		1,732,191			1,562,499	1,196,503						1,562,499
Loan interest - related party																																																														69,669	43,715						69,669
Royalty payable to related party																																																														65,292	65,292
Chief Executive Officer [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Loan interest - related party																																																														82,238							82,238
Mr. Jonathan R. Rice [Member]
Related Party Transaction [Line Items]
Payroll payable																																																									29,943		29,943			103,730	64,352						103,730
Mr. Kenneth Le [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																									3,018		3,018			$ 888							$ 888
Stockholder [Member]
Related Party Transaction [Line Items]
Debt Instrument, interest rate																																																														3.00%							3.00%
Interest expense and related accrued interest payable																																																														$ 36,562	15,581						$ 36,562
Loan received	$ 70,000	$ 35,000	$ 30,000	$ 30,000	$ 100,000	$ 100,000	$ 100,000	$ 150,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000											$ 20,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 17,000	$ 3,000	$ 17,000	$ 20,000	$ 11,000	$ 26,000	$ 26,000	$ 20,000	$ 15,000	$ 15,000	$ 20,000	$ 20,000	$ 15,000	$ 15,000		$ 100,000	$ 100,000	$ 30,000		$ 50,000	$ 50,000																		$ 30,000
Loans payable																																																									1,657,000		1,657,000			1,657,000	642,000						1,657,000
In-kind contribution of interest																																																														50,763	22,337
Chief Executive Officer And Chief Operations Officer [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued expenses																																																									338,049		338,049			331,143	304,539						331,143
Director of Prodigy Textiles [Member]
Related Party Transaction [Line Items]
Payroll payable																																																									26,110		26,110
Principal Stockholder [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																														2,804,725	2,535,203						2,804,725
Office Employee [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																														22,900	4,477						22,900
Mr.Rice [Member]
Related Party Transaction [Line Items]
Payroll payable																																																															64,351
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																														103,730	64,351						103,730
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Accrued salary balance																																																										$ 3,018		$ 3,018		888	$ 1,153						888
Intellectual Property Transfer Agreement [Member] | Mr. Thompson [Member]
Related Party Transaction [Line Items]
Number of shares issued																																																							200,000
Dividends preferred stock																																																							$ 0
Preferred stock voting rights																																																							voting rights equal to 100 common shares per share of preferred stock	voting rights equal to 100 common shares per share of preferred stock
Stock issued during period, value																																																							$ 120,000
Fair value of the payment																																																							$ 120,000	$ 120,000															$ 120,000
Debt instrument term, description																																																							one year
Outstanding balance																																																									$ 65,292		$ 65,292			$ 65,292							$ 65,292
Debt Instrument, interest rate																																																									7.00%		7.00%			7.00%							7.00%
Interest expense and related accrued interest payable																																																									$ 9,483		$ 9,483			$ 8,503							$ 8,503
Employment Agreement [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Agreement term																																																															5 years
Annual salary																																																															$ 334,708
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Related Party Transaction [Line Items]
Warrants term, description																						three-year
Employment Agreement [Member]
Related Party Transaction [Line Items]
Extended expiration date description																																												the Company extended the expiration date of a warrant for 2,000,000 shares of common stock from January 19, 2018 to January 31, 2020 and on January 10, 2020, the Company extended the expiration date of the warrant to January 10, 2025 for Mr. Rice.
Employment Agreement [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Agreement term																																																						5 years								5 years	5 years	5 years	5 years	5 years
Annual salary																																																						$ 210,000							$ 398,643	$ 376,078	$ 354,791	$ 315,764	$ 297,889	$ 297,889	$ 281,027
Accrued salary balance																																																														2,804,725	2,535,203						2,804,725
Employment Agreement [Member] | Mr. Jonathan R. Rice [Member]
Related Party Transaction [Line Items]
Agreement term																																																				1 year	1 year
Annual salary															$ 20,000			$ 20,000	$ 20,000				$ 20,000
Annual cash compensation																																																				$ 140,000	$ 120,000
Warrants term, description																																																			three-year	three
Warrant to purchase shares																																																			6,000,000	6,000,000																		6,000,000
Warrant exercise price per share																																																			$ 0.001	$ 0.001																		$ 0.2299
Extended expiration date description																																												the Company extended the expiration date of the January 2015 warrant from January 19, 2018 to January 31, 2020, and on January 10, 2020 the Company extended the expiration date of the January 2015 warrant to January 10, 2025 and on March 15, 2018, the Company signed an extension of its at-will employment agreement with its COO, extending the term to January 31, 2019.
One-time bonus																							$ 20,000
Working capital															$ 6,000,000			$ 6,000,000	$ 6,000,000
Ownership percentage															50.00%			50.00%	50.00%
Employment Agreement [Member] | Mr. Kenneth Le [Member]
Related Party Transaction [Line Items]
Agreement term																						1 year
Accrued salary balance																																																														888	1,154						$ 888
Annual cash compensation																						$ 60,000
Warrants term, description																					three	three-year
Warrant to purchase shares																					2,000,000	2,000,000
Warrant exercise price per share																					$ 0.2299	$ 0.2299
Operating Lease Agreements [Member]
Related Party Transaction [Line Items]
Payments for rent																	$ 44,800																																													2,508
Operating Lease Agreements [Member] | President [Member]
Related Party Transaction [Line Items]
Payments for rent																																																$ 960														960
Operating leases, rent expense																																																														$ 13,092	$ 14,793

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)

Jul. 29, 2021USD ($)shares

Jul. 20, 2021USD ($)shares

Jul. 06, 2021USD ($)shares

Mar. 03, 2021USD ($)

Mar. 02, 2021USD ($)shares

Jan. 25, 2021USD ($)$ / sharesshares

Sep. 26, 2019shares

Aug. 14, 2019shares

Mar. 20, 2019USD ($)shares

Dec. 31, 2019USD ($)

Jul. 01, 2021USD ($)ft²

Jun. 30, 2021USD ($)

Dec. 31, 2020USD ($)

Jun. 30, 2020USD ($)

Sep. 05, 2019ft²

Subsequent Event [Line Items]

Number of shares issued | shares

766,667

7,967,871

4,052,652

Stock issued during period, value

$ 281,659

$ 1,000,000

Area of Land | ft²

5,000

Lessee, Operating Lease, Liability, to be Paid

$ 559,568

Interest Payable

15,581

$ 108,900

36,562

$ 14,161

Related Party [Member]

Subsequent Event [Line Items]

Interest Payable

$ 1,196,503

$ 1,732,191

$ 1,562,499

Subsequent Event [Member]

Subsequent Event [Line Items]

Number of shares issued | shares

3,101,546

1,664,823

2,343,919

Lessee, Operating Lease, Term of Contract

5 years

Area of Land | ft²

36,000

Lessee, Operating Lease, Liability, to be Paid

$ 9,570

Debt Conversion, Original Debt, Amount

$ 200,000

$ 100,000

$ 200,000

Interest Payable

$ 11,836

$ 60,822

$ 7,671

Subsequent Event [Member] | Paycheck Protection Program Loan [Member]

Subsequent Event [Line Items]

Proceeds from loan

$ 901,000

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Number of shares issued | shares

1,479,728

Stock issued during period, value

$ 88,783.68

Subsequent Event [Member] | Related Party [Member] | Employee Stock Option Plan [Member]

Subsequent Event [Line Items]

Stock issued during period shares, options | shares

2,500,000

Exercise price | $ / shares

$ 0.134

Subsequent Event [Member] | Kings Group [Member] | Strategic Partnership Agreement [Member]

Subsequent Event [Line Items]

Related party transaction amount

$ 40,000,000

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Income tax rate	21.00%	21.00%

SCHEDULE OF DEFERRED TAX ASSE_2

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Expected income tax (recovery) expense at the statutory rate of 21%					$ (1,043,948)	$ (610,845)
Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes)					608,152	142,167
Change in valuation allowance					435,795	468,678
Provision for income taxes

SCHEDULE OF COMPONENTS DEFERRED

SCHEDULE OF COMPONENTS DEFERRED INCOME TAXES (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Operating Loss Carryforward	$ 3,815,336	$ 3,379,542
Valuation allowance	(3,815,336)	(3,379,542)
Net deferred tax asset
Net deferred tax liability